{"content":"<li class=\"n-box-item date-title\" data-end=\"1505793599\" data-start=\"1505707200\" data-txt=\"Monday, December 23, 2019\">Monday, September 18, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3296182\" data-ts=\"1505770535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296182-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a> <font color='green'>+5.5%</font>. <a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='green'>+5.3%</font>. <a href='https://seekingalpha.com/symbol/TOO' title='Teekay Offshore Partners L.P.'>TOO</a> <font color='green'>+3.9%</font>. <a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='green'>+3.6%</font>. <a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a> <font color='green'>+3.2%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a> <font color='red'>-4.9%</font>. <a href='https://seekingalpha.com/symbol/BECN' title='Beacon Roofing Supply, Inc.'>BECN</a> <font color='red'>-4.7%</font>. <a href='https://seekingalpha.com/symbol/SUPN' title='Supernus Pharmaceuticals, Inc.'>SUPN</a> <font color='red'>-4.4%</font>. BBG <font color='red'>-4.4%</font>. <a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color='red'>-2.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296182\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$NBRV $DRNA $TOO - After Hours Gainers / Losers https://seekingalpha.com/news/3296182-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3296182-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296174\" data-ts=\"1505768264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDWD\" target=\"_blank\">MDWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296174-mediwound-readies-equity-offering-shares-down-14-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MediWound readies equity offering; shares down 14% after hours</a></h4><ul><li>Thinly traded micro cap MediWound Ltd. (NASDAQ:<a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a>) is down&nbsp;<font color='red'>14%</font>&nbsp;after hours on light volume in response to its <a href=\"https://seekingalpha.com/pr/16943827-mediwound-ltd-announces-public-offering-ordinary-shares\" target=\"_blank\">planned public offering</a> of ordinary shares. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296174\" data-linked=\"MediWound readies equity offering; shares down 14% after hours\" data-tweet=\"$MDWD - MediWound readies equity offering; shares down 14% after hours https://seekingalpha.com/news/3296174-mediwound-readies-equity-offering-shares-down-14-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3296174-mediwound-readies-equity-offering-shares-down-14-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296173\" data-ts=\"1505768062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBRV\" target=\"_blank\">NBRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296173-nabriva-readies-equity-offering-shares-up-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nabriva readies equity offering; shares up 5% after hours</a></h4><ul><li>Nabriva Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a>) <a href=\"https://seekingalpha.com/pr/16943824-nabriva-therapeutics-announces-proposed-public-offering-ordinary-shares\" target=\"_blank\">launches </a>an $80M public offering of ordinary shares. Price, volume and terms have yet to be released.</li><li>Shares are up&nbsp;<font color='green'>5%&nbsp;</font>after hours on robust volume but certainly could swing lower. The past two trading days have seen an extraordinarily large trading range, from $6.52 to $14.10. The action was stoked this morning by its announcement of positive Phase 3 results for antibiotic lefamulin.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295964-nabrivas-lefamulin-successful-late-stage-cabp-study-shares-ahead-92-percent-premarket\" target=\"_blank\">Nabriva's lefamulin successful in late-stage CABP study; shares ahead 92% premarket</a> (Sept. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296173\" data-linked=\"Nabriva readies equity offering; shares up 5% after hours\" data-tweet=\"$NBRV - Nabriva readies equity offering; shares up 5% after hours https://seekingalpha.com/news/3296173-nabriva-readies-equity-offering-shares-up-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3296173-nabriva-readies-equity-offering-shares-up-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296171\" data-ts=\"1505767468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLF\" target=\"_blank\">HLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296171-herbalife-extends-deadline-for-600m-offer-for-shares-includes-cvr-for-go-private-transaction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herbalife extends deadline for $600M offer for shares, includes CVR for go-private transaction; shares up 1% after hours</a></h4><ul><li>Herbalife (NYSE:<a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a>) has <a href=\"https://www.sec.gov/Archives/edgar/data/1180262/000119312517287302/d455209dsctoia.htm\" target=\"_blank\">extended </a>its $600M tender offer for common shares to October 5, unless further extended. Sellers will receive between $60 - 68 per share and a Contingent Value Right &#40;CVR&#41; that pays out if the company goes private.</li><li>The <a href=\"https://seekingalpha.com/pr/16943831-herbalife-announces-amendment-extension-tender-offer-common-shares\" target=\"_blank\">deadline </a>was extended to allow sellers to evaluate the SEC-requested amendments to the original offer.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290625-herbalife-launches-offer-buy-600m-common-stock-sellers-receive-cvr-go-private-deal-shares-8\" target=\"_blank\">Herbalife launches offer to buy $600M of common stock, sellers to receive CVR for go-private deal; shares up 8% premarket</a> (Aug. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296171\" data-linked=\"Herbalife extends deadline for $600M offer for shares, includes CVR for go-private transaction; shares up 1% after hours\" data-tweet=\"$HLF - Herbalife extends deadline for $600M offer for shares, includes CVR for go-private transaction; shares up 1% after hours https://seekingalpha.com/news/3296171-herbalife-extends-deadline-for-600m-offer-for-shares-includes-cvr-for-go-private-transaction?source=tweet\" data-url=\"https://seekingalpha.com/news/3296171-herbalife-extends-deadline-for-600m-offer-for-shares-includes-cvr-for-go-private-transaction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>89&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296156\" data-ts=\"1505766301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDX\" target=\"_blank\">ALDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296156-aldeyra-readies-equity-offering-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aldeyra readies equity offering; shares down 7% after hours</a></h4><ul><li>Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) slips&nbsp;<font color='red'>7%</font>&nbsp;after hours on average volume in response to its <a href=\"https://seekingalpha.com/pr/16943799-aldeyra-therapeutics-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">planned stock offering</a>. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296156\" data-linked=\"Aldeyra readies equity offering; shares down 7% after hours\" data-tweet=\"$ALDX - Aldeyra readies equity offering; shares down 7% after hours https://seekingalpha.com/news/3296156-aldeyra-readies-equity-offering-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3296156-aldeyra-readies-equity-offering-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296150\" data-ts=\"1505765980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUPN\" target=\"_blank\">SUPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296150-supernus-pharmas-late-stage-study-supporting-ia-candidate-spnminus-810-to-continue-planned\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Supernus Pharma&#39;s late-stage study supporting IA candidate SPN-810 to continue as planned, lower dose eliminated</a></h4><ul><li>An <a href=\"https://seekingalpha.com/pr/16943804-supernus-provides-update-spnminus-810-phase-iii-clinical-trials\" target=\"_blank\">interim analysis</a> by an independent statistician concludes that the first of two Phase 3 clinical trials assessing Supernus Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/SUPN' title='Supernus Pharmaceuticals, Inc.'>SUPN</a>) SPN-810 for the treatment of impulsive aggression &#40;IA&#41; in children 6 - 12 years old should continue as planned, randomizing participants to the 36 mg dose arm or placebo. The lower dose of 18 mg will be terminated.</li><li>Enrollment will continue through mid-2018.</li><li>SPN-810 (molindone hydrochloride) was originally marketed under the brand name Moban for schizophrenia by Endo Pharmaceuticals, who <a href=\"https://en.wikipedia.org/wiki/Molindone\" target=\"_blank\">ceased supplying</a> the product in January 2010. A generic version is currently being sold in the U.S. by privately held CorePharma.</li><li>The company will host a conference call today at 5:00 pm ET to discuss the data.</li><li>Trading in SUPN, currently suspended, will resume at 4:30 pm ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296150\" data-linked=\"Supernus Pharma&#39;s late-stage study supporting IA candidate SPN-810 to continue as planned, lower dose eliminated\" data-tweet=\"$SUPN - Supernus Pharma&#39;s late-stage study supporting IA candidate SPN-810 to continue as planned, lower dose eliminated https://seekingalpha.com/news/3296150-supernus-pharmas-late-stage-study-supporting-ia-candidate-spnminus-810-to-continue-planned?source=tweet\" data-url=\"https://seekingalpha.com/news/3296150-supernus-pharmas-late-stage-study-supporting-ia-candidate-spnminus-810-to-continue-planned\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296146\" data-ts=\"1505765753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BECN\" target=\"_blank\">BECN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296146-beacon-roofing-supply-announces-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Beacon Roofing Supply announces share offering</a></h4><ul> <li>Beacon Roofing Supply (NASDAQ:<a href='https://seekingalpha.com/symbol/BECN' title='Beacon Roofing Supply, Inc.'>BECN</a>)&nbsp;announces a $300M share offering. The company will also grant the       underwriters a 30-day option to purchase up to an additional $45M in shares.</li>     <li>Beacon expects to use proceeds to help finance the previously announced acquisition of Allied Building Products Corp.</li><li>BECN  <font color='red'>-5.32%</font> after hours to  $46.60.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16943828-beacon-roofing-supply-inc-announces-public-offering-common-stock\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3296146\" data-linked=\"Beacon Roofing Supply announces share offering\" data-tweet=\"$BECN - Beacon Roofing Supply announces share offering https://seekingalpha.com/news/3296146-beacon-roofing-supply-announces-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3296146-beacon-roofing-supply-announces-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296139\" data-ts=\"1505765252\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCS\" target=\"_blank\">SCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296139-steelcase-beats-0_08-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steelcase beats by $0.08, beats on revenue</a></h4><ul><li>Steelcase (NYSE:<a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a>): Q2 EPS of $0.31 <font color='green'>beats by $0.08</font>.</li><li>Revenue of $775.6M (+2.3% Y/Y) <font color='green'>beats by $15.77M</font>.</li><li>Shares <font color='green'>+4.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16943825-steelcase-reports-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3296139\" data-linked=\"Steelcase beats by $0.08, beats on revenue\" data-tweet=\"$SCS - Steelcase beats by $0.08, beats on revenue https://seekingalpha.com/news/3296139-steelcase-beats-0_08-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3296139-steelcase-beats-0_08-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296138\" data-ts=\"1505765244\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCS\" target=\"_blank\">SCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296138-steelcase-beats-0_08-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steelcase beats by $0.08, beats on revenue</a></h4><ul><li>Steelcase (NYSE:<a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a>): Q2 EPS of $0.31 <font color='green'>beats by $0.08</font>.</li><li>Revenue of $775.6M (+2.3% Y/Y) <font color='green'>beats by $15.77M</font>.</li><li>Shares <font color='green'>+4.5%</font>.</li><li><a href='https://seekingalpha.com/pr/16943825-steelcase-reports-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3296138\" data-linked=\"Steelcase beats by $0.08, beats on revenue\" data-tweet=\"$SCS - Steelcase beats by $0.08, beats on revenue https://seekingalpha.com/news/3296138-steelcase-beats-0_08-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3296138-steelcase-beats-0_08-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296133\" data-ts=\"1505764934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUPN\" target=\"_blank\">SUPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296133-supernus-pharma-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Supernus Pharma trading halted pending news</a></h4><ul><li>Nasdaq has <a href=\"http://www.nasdaqtrader.com/trader.aspx?id=tradehalts\" target=\"_blank\">suspended </a>trading in Supernus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SUPN' title='Supernus Pharmaceuticals, Inc.'>SUPN</a>) pending the release of news.</li><li>A month ago, the company prevailed in patent litigation related to antiseizure med Oxtellar XR (oxcarbazepine).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289671-supernus-pharma-rebuffs-second-generic-challenger-oxtellar-xr\" target=\"_blank\">Supernus Pharma rebuffs second generic challenger to Oxtellar XR</a> (Aug. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296133\" data-linked=\"Supernus Pharma trading halted pending news\" data-tweet=\"$SUPN - Supernus Pharma trading halted pending news https://seekingalpha.com/news/3296133-supernus-pharma-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3296133-supernus-pharma-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296127\" data-ts=\"1505764037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLUG\" target=\"_blank\">PLUG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296127-plug-power-up-nearly-9-after-insider-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plug Power up nearly 9% after insider buy</a></h4><ul><li>Co-founder and Chairman George McNamee <a href=\"https://seekingalpha.com/filing/3699778\" target=\"_blank\">today disclosed the purchase</a> of 200K shares over about a one-week period ending Sept. 15. He paid in the range of $2.13-$2.34 per share.</li><li><a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a>&nbsp;<font color='green'>+8.6%</font>&nbsp;to $2.44.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296127\" data-linked=\"Plug Power up nearly 9% after insider buy\" data-tweet=\"$PLUG - Plug Power up nearly 9% after insider buy https://seekingalpha.com/news/3296127-plug-power-up-nearly-9-after-insider-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3296127-plug-power-up-nearly-9-after-insider-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296125\" data-ts=\"1505763718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CASI\" target=\"_blank\">CASI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296125-casi-pharma-adds-to-up-move-shares-ahead-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CASI Pharma adds to up move; shares ahead 24%</a></h4><ul><li>Thinly traded micro cap CASI Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a> <font color='green'>+24%</font>) jumps again, this time on a 23x surge in volume. Shares had doubled since last week before retracing modestly.</li><li>About two weeks ago, the company updated investors on its pipeline, including designation of Priority Review status for multiple myeloma candidate EVOMELA (melphalan) by the Chinese Food and Drug Administration.</li><li>The company is pursuing Import Drug registration for EVOMELA, MARQIBO and ZEVALIN, all in-licensed from Spectrum Pharmaceuticals.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294112-casi-provides-pipeline-development-update\" target=\"_blank\">CASI provides pipeline development update</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296125\" data-linked=\"CASI Pharma adds to up move; shares ahead 24%\" data-tweet=\"$CASI - CASI Pharma adds to up move; shares ahead 24% https://seekingalpha.com/news/3296125-casi-pharma-adds-to-up-move-shares-ahead-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3296125-casi-pharma-adds-to-up-move-shares-ahead-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296118\" data-ts=\"1505762650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYES\" target=\"_blank\">EYES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296118-second-sight-perks-up-on-article-orion-implant-in-mit-journal-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Second Sight perks up on article about Orion implant in MIT journal; shares up 4%</a></h4><ul><li>Thinly traded nano cap Second Sight Medical (<a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='green'>+3.6%</font>) was up over&nbsp;<font color='green'>7%&nbsp;</font>before retracing on 33% higher volume. The spark appears to be an <a href=\"https://www.technologyreview.com/s/608844/blind-patients-to-test-bionic-eye-brain-implants/\" target=\"_blank\">article </a>published today in the MIT's Technology Review about its new implant, the Orion, a modified version of the Argus II Retinal Prosthesis System.</li><li>Orion, which is based on 90% of the technology in Argus, involves the placement of an array of electrodes on the part of the brain that processes visual information.</li><li>The FDA has signed off a small five-subject study to further test the device before starting larger-scale trials.</li><li>Progress will be slow, however. Martha Flanders, Director of the Central Visual Processing Program at the National Eye Institute says the brain implant will be much harder to \"get right\" than a retinal implant because of the complexity of the brain's visual cortex, adding that scientists are still don't know much about how the brain processes images to produce vision and how neurons extract information from that part of the brain.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296118\" data-linked=\"Second Sight perks up on article about Orion implant in MIT journal; shares up 4%\" data-tweet=\"$EYES - Second Sight perks up on article about Orion implant in MIT journal; shares up 4% https://seekingalpha.com/news/3296118-second-sight-perks-up-on-article-orion-implant-in-mit-journal-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3296118-second-sight-perks-up-on-article-orion-implant-in-mit-journal-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296119\" data-ts=\"1505762161\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296119-trudeau-may-to-press-trump-to-intervene-in-boeing-bombardier-rift\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trudeau, May to press Trump to intervene in Boeing-Bombardier rift</a></h4><ul>     <li>Prime Minister Justin Trudeau says Canada <a href=\"https://www.bloomberg.com/news/articles/2017-09-18/trudeau-says-canada-won-t-buy-boeing-jets-amid-bombardier-fight\" target=\"_blank\">will not buy</a> Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='green'>+1.7%</font>) fighter jets while the company pursues a trade challenge against Bombardier (<a href='https://seekingalpha.com/symbol/BDRAF' title='Bombardier Inc.A'>OTCQX:BDRAF</a>, <a href='https://seekingalpha.com/symbol/BDRBF' title='Bombardier Inc.B'>OTCQX:BDRBF</a>) over the C&nbsp;Series commercial aircraft.</li>     <li>Trudeau made his threat to halt Canada&rsquo;s $5.2B list price purchase of F-18 Super Hornets alongside U.K. Prime Minister Theresa May at a meeting today of the two leaders who are pressing Boeing to drop its challenge.</li>     <li>May says she will <a href=\"http://www.reuters.com/article/us-canada-britain/britains-may-says-will-press-trump-this-week-on-bombardier-boeing-row-idUSKCN1BT27C?il=0\" target=\"_blank\">press Pres. Trump</a> this week about BA's trade challenge, which she says could endanger thousands of aerospace jobs in Northern Ireland.</li>     <li>The U.S. Commerce Department is investigating whether to impose countervailing duties on the Bombardier planes, with a preliminary ruling expected Sept. 25 and a separate decision on anti-dumping duties expected Oct. 4; final determinations and orders are not likely until 2018.</li>     <li>Meanwhile, BA extends the rally that has carried shares nearly 8% higher since Sept 6, now trading at <a href=\"http://www.marketwatch.com/story/boeing-record-rally-adds-more-than-80-points-to-dow-industrials-so-far-in-september-2017-09-18\" target=\"_blank\">all-time highs</a>; it is the biggest gainer YTD for the Dow, up 62.5%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296119\" data-linked=\"Trudeau, May to press Trump to intervene in Boeing-Bombardier rift\" data-tweet=\"$BA $BA $BDRAF - Trudeau, May to press Trump to intervene in Boeing-Bombardier rift https://seekingalpha.com/news/3296119-trudeau-may-to-press-trump-to-intervene-in-boeing-bombardier-rift?source=tweet\" data-url=\"https://seekingalpha.com/news/3296119-trudeau-may-to-press-trump-to-intervene-in-boeing-bombardier-rift\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296120\" data-ts=\"1505761917\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FANH\" target=\"_blank\">FANH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296120-fanhua-announces-dividend-policy-and-increase-of-dividend-payout-ratio-sharesplus-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fanhua announces dividend policy and increase of dividend payout ratio; shares +15%</a></h4><ul>     <li>Fanhua (NASDAQ:<a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a>) announced that its board has modified its dividend policy to adopt a quarterly payment schedule in lieu of an annual dividend.&nbsp;The Company expects to declare the first quarterly dividend by the end of November.</li>     <li>Under the revised policy, dividends will be declared and paid on a quarterly basis, at an amount equivalent to no less than 50% of net income attributable to the Company's shareholders in each quarter instead of no less than 30% under the annual dividend policy previously announced on April 20, 2017.</li>     <li>Shares&nbsp;<font color='green'>+15%</font></li><li><a href=\"https://seekingalpha.com/pr/16943319-fanhua-announces-quarterly-dividend-policy-increase-dividend-payout-ratio\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3296120\" data-linked=\"Fanhua announces dividend policy and increase of dividend payout ratio; shares +15%\" data-tweet=\"$FANH - Fanhua announces dividend policy and increase of dividend payout ratio; shares +15% https://seekingalpha.com/news/3296120-fanhua-announces-dividend-policy-and-increase-of-dividend-payout-ratio-sharesplus-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3296120-fanhua-announces-dividend-policy-and-increase-of-dividend-payout-ratio-sharesplus-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296116\" data-ts=\"1505761158\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NC\" target=\"_blank\">NC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296116-nacco-industries-declares-hamilton-beach-brands-holding-stock-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NACCO Industries declares Hamilton Beach Brands Holding stock dividend</a></h4><ul>     <li>NACCO Industries (<a href='https://seekingalpha.com/symbol/NC' title='NACCO Industries Inc.'>NC</a> <font color='green'>+7.6%</font>) declared a stock dividend of one share of Hamilton Beach Brands Holding Company Class A common stock and one share of Hamilton Beach Holding Class B common stock for each share of NACCO Industries Class A or Class B common stock outstanding.</li>     <li>The distribution has been structured to qualify as a tax free dividend to NACCO shareholders for U.S. federal income tax purposes.</li>     <li>Hamilton Beach Holding has filed an application to list its Class A common stock on the New York Stock Exchange under the trading symbol \"HBB\". Hamilton Beach Holding Class B common stock will not be listed on the NYSE and each share is convertible into one share of Hamilton Beach Holding Class A common stock at any time without cost at the option of the holder.</li>     <li>The stock dividend will be distributed on Sept. 29, 2017 to stockholders of record at the close of business on Sept. 26, 2017.</li><li><a href=\"https://seekingalpha.com/pr/16943633-nacco-industries-declares-hamilton-beach-brands-holding-stock-dividend\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3296116\" data-linked=\"NACCO Industries declares Hamilton Beach Brands Holding stock dividend\" data-tweet=\"$NC $HBB - NACCO Industries declares Hamilton Beach Brands Holding stock dividend https://seekingalpha.com/news/3296116-nacco-industries-declares-hamilton-beach-brands-holding-stock-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3296116-nacco-industries-declares-hamilton-beach-brands-holding-stock-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296113\" data-ts=\"1505760904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296113-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LOV' title='Spark Networks, Inc'>LOV</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/SSNI' title='Silver Spring Networks'>SSNI</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/GVP' title='GSE Systems, Inc'>GVP</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/COHU' title='Cohu, Inc.'>COHU</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZDGE' title='Zedge, Inc.'>ZDGE</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/KEYW' title='KEYW Holding'>KEYW</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SMCI' title='Super Micro Computer, Inc.'>SMCI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/UBNT' title='Ubiquiti Networks, Inc.'>UBNT</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296113\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$LOV $SSNI $GVP - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3296113-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296113-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296110\" data-ts=\"1505759650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAT\" target=\"_blank\">CAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296110-caterpillar-rallies-to-new-record-highs-after-ubs-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caterpillar rallies to new record highs after UBS upgrade</a></h4><ul>     <li>Caterpillar (<a href='https://seekingalpha.com/symbol/CAT' title='Caterpillar Inc.'>CAT</a> <font color='green'>+2%</font>) pushes to new <a href=\"http://www.marketwatch.com/story/caterpillars-stock-runs-up-to-record-after-ubs-raises-rating-price-target-2017-09-18\" target=\"_blank\">all-time highs</a> after UBS <a href=\"https://seekingalpha.com/news/3295948-caterpillar-upgraded-buy-ubs\" target=\"_blank\">turned bullish</a> on the stock, believing that its earnings upcycle will continue given a growing cash position.</li>     <li>UBS says its latest analysis of private non-residential construction suggests activity will accelerate in Q4, with 60% of mining companies surveyed expecting new equipment budgets will increase in 2018 while more than half plan to rebuild fleets within the next 12 months.</li>     <li>CAT will generate nearly $10B in cash flow during 2018-20 after capital spending and dividend payments, which could be strategically redeployed or returned to shareholders, UBS says.</li>     <li>Tigress Financial thinks autonomy is <a href=\"http://www.barrons.com/articles/caterpillar-autonomous-driving-isnt-just-for-cars-1505753124\" target=\"_blank\">another reason to be bullish</a>: \"CAT is equipping its machinery with fully autonomous and remote-control capabilities that can completely run a job site... This increases efficiency and safety significantly and creates a new opportunity for the sale and upgrade of Caterpillar equipment.\"</li>     <li>CAT shares are up 33%&nbsp;YTD vs. 13% for the Dow and 12% for the SPDR Industrial Select Sector ETF (<a href='https://seekingalpha.com/symbol/XLI' title='Industrial Select Sector SPDR ETF'>XLI</a> <font color='green'>+0.5%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3296110\" data-linked=\"Caterpillar rallies to new record highs after UBS upgrade\" data-tweet=\"$CAT $CAT $XLI - Caterpillar rallies to new record highs after UBS upgrade https://seekingalpha.com/news/3296110-caterpillar-rallies-to-new-record-highs-after-ubs-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3296110-caterpillar-rallies-to-new-record-highs-after-ubs-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296107\" data-ts=\"1505758381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TISI\" target=\"_blank\">TISI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296107-team-inc-ceo-owen-out-ceo-yesavage-named-interim-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Team Inc. CEO Owen out as CEO; Yesavage named interim CEO</a></h4><ul>     <li>Industrial services company Team Inc. (<a href='https://seekingalpha.com/symbol/TISI' title='Team, Inc.'>TISI</a> <font color='green'>+2.2%</font>) is higher following news that Ted Owen has <a href=\"https://seekingalpha.com/pr/16943011-team-inc-announces-leadership-changes\" target=\"_blank\">stepped down as CEO</a> and board member and former Chevron executive Gary Yesavage is appointed interim CEO.</li>     <li>The move follows a letter last week from Engine Capital Management that largely <a href=\"http://www.chron.com/business/energy/article/Team-Inc-CEO-steps-down-after-calls-for-his-12206023.php\" target=\"_blank\">blamed Owen</a> for the 65% YTD loss in Team's stock value and called for his removal.</li>     <li>Owen took over the CEO job three years ago and led the company through acquisitions of Furmanite and QualSpec, but Engine Capital criticized Team for overpaying for both and failing to efficiently integrate the companies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296107\" data-linked=\"Team Inc. CEO Owen out as CEO; Yesavage named interim CEO\" data-tweet=\"$TISI - Team Inc. CEO Owen out as CEO; Yesavage named interim CEO https://seekingalpha.com/news/3296107-team-inc-ceo-owen-out-ceo-yesavage-named-interim-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3296107-team-inc-ceo-owen-out-ceo-yesavage-named-interim-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296106\" data-ts=\"1505758293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296106-loonie-lower-boc-signals-concern\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loonie lower as BOC signals concern</a></h4><ul><li>The loonie (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXC' title='CurrencyShares Canadian Dollar Trust ETF'>FXC</a>) has lost about 75 pips vs. the dollar in the last few minutes after Bank of Canada Deputy Governor Timothy Lane <a href=\"http://www.reuters.com/article/us-canada-bank/bank-of-canada-watching-impact-of-higher-rates-stronger-c-lane-idUSKCN1BT2AD?il=0\" target=\"_blank\">says the bank will pay</a> close attention to economy's response to both higher rates and the stronger Canadian dollar.</li><li>The loonie is &nbsp;now<font color='red'> lower by 1%</font>&nbsp;vs. the greenback to $0.8122.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/EWC' title='iShares MSCI Canada ETF'>EWC</a>, <a href='https://seekingalpha.com/symbol/CNDA' title='IQ Canada Small Cap ETF'>CNDA</a>, <a href='https://seekingalpha.com/symbol/EWCS' title='iShares MSCI Canada Small Cap Index ETF'>EWCS</a>, <a href='https://seekingalpha.com/symbol/QCAN' title='SPDR MSCI Canada Quality Mix ETF'>QCAN</a>, <a href='https://seekingalpha.com/symbol/FCAN' title='First Trust Canada AlphaDex ETF'>FCAN</a>, <a href='https://seekingalpha.com/symbol/HEWC' title='iShares Currency Hedged MSCI Canada ETF'>HEWC</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3296106\" data-linked=\"Loonie lower as BOC signals concern\" data-tweet=\"$FXC $EWC $CNDA - Loonie lower as BOC signals concern https://seekingalpha.com/news/3296106-loonie-lower-boc-signals-concern?source=tweet\" data-url=\"https://seekingalpha.com/news/3296106-loonie-lower-boc-signals-concern\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296104\" data-ts=\"1505757701\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLED\" target=\"_blank\">OLED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296104-goldman-sachs-raises-universal-display-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs raises Universal Display price target</a></h4><ul><li>        Goldman Sachs <a href=\"https://www.streetinsider.com/Analyst+Comments/Universal+Display+%28OLED%29+PT+Raised+to+%24161+at+Goldman+Sachs%2C+Street+High/13304975.html\" target=\"_blank\">raises</a> its Universal Display (NASDAQ:<a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a>) price target to $161 from $150 and maintains a Buy rating.</li><li>                  Analyst Brian Lee expects Universal Display to add somewhere in the broad range of 16% to 66% to its out-year EPS, putting the stock price from $178 to $254.    </li><li>               Lee says adding blue materials, the most popular type of OLED material, could more than double its revenue content.&nbsp;</li><li>               Universal Display shares are&nbsp;<font color='green'>up 3.48%.</font>&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3296104\" data-linked=\"Goldman Sachs raises Universal Display price target\" data-tweet=\"$OLED - Goldman Sachs raises Universal Display price target https://seekingalpha.com/news/3296104-goldman-sachs-raises-universal-display-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3296104-goldman-sachs-raises-universal-display-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296102\" data-ts=\"1505757659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296102-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PZG' title='Paramount Gold Nevada Corp.'>PZG</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/XCO' title='EXCO Resources, Inc.'>XCO</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ESES' title='Eco-Stim Energy Solutions, Inc.'>ESES</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ALO' title='Alio Gold Inc'>ALO</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/PQ' title='PetroQuest Energy Inc.'>PQ</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296102\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$PZG $XCO $ESES-OLD - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3296102-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296102-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296100\" data-ts=\"1505756989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FATE\" target=\"_blank\">FATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296100-fate-therapeutics-launches-mid-stage-study-of-protmune-in-gvhd-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fate Therapeutics launches mid-stage study of ProTmune in GvHD; shares ahead 3%</a></h4><ul><li>Fate Therapeutics (<a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a> <font color='green'>+2.6%</font>) initiates the Phase 2 segment of its Phase 1/2 clinical trial, PROTECT, assessing ProTmune for the prevention of acute graft-versus-host disease (GvHD) in patients with blood cancers undergoing matched unrelated donor hematopoietic cell transplantation &#40;HCT&#41;.</li><li>The Phase 2 will evaluate the safety and efficacy of ProTmune in 60 patients who will be randomized 1:1 to receive either ProTmune or a conventional matched unrelated donor mobilized peripheral blood cell graft. The primary endpoint is the incidence of acute GvHD by day 100 post-HCT.</li><li><a href=\"http://fatetherapeutics.com/product-pipeline/immuno-protection-franchise/protmune/\" target=\"_blank\">ProTmune&nbsp;</a>is a programmed cellular immunotherapy that is designed for use as an allogeneic hematopoietic cell source for HCT. It is produced by modulating mobilized peripheral blood with two small molecules to enhance the biological properties and therapeutic function of immune cells.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3189608-fate-therapeutics-protmune-fast-trackd-gvhd-shares-18-percent-premarket\" target=\"_blank\">Fate Therapeutics' ProTmune Fast Track'd for GvHD; shares up 18% premarket</a> (June 20, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296100\" data-linked=\"Fate Therapeutics launches mid-stage study of ProTmune in GvHD; shares ahead 3%\" data-tweet=\"$FATE - Fate Therapeutics launches mid-stage study of ProTmune in GvHD; shares ahead 3% https://seekingalpha.com/news/3296100-fate-therapeutics-launches-mid-stage-study-of-protmune-in-gvhd-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3296100-fate-therapeutics-launches-mid-stage-study-of-protmune-in-gvhd-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296098\" data-ts=\"1505756207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VYGR\" target=\"_blank\">VYGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296098-new-operating-chief-voyager-therapeutics-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New operating chief at Voyager Therapeutics; shares up 5%</a></h4><ul><li>Voyager Therapeutics (<a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics'>VYGR</a> <font color='green'>+4.7%</font>) <a href=\"https://seekingalpha.com/pr/16943212-voyager-therapeutics-appoints-matthew-p-ottmer-chief-operating-officer\" target=\"_blank\">appoints </a>Matthew Ottmer as Chief Operating Officer. He joins the firm from Momenta Pharmaceuticals were he was also COO.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296098\" data-linked=\"New operating chief at Voyager Therapeutics; shares up 5%\" data-tweet=\"$VYGR - New operating chief at Voyager Therapeutics; shares up 5% https://seekingalpha.com/news/3296098-new-operating-chief-voyager-therapeutics-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3296098-new-operating-chief-voyager-therapeutics-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296095\" data-ts=\"1505755261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVNS\" target=\"_blank\">AVNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296095-halyards-coolief-beats-steroid-injections-in-treating-osteoarthritis-related-knee-pain-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halyard&#39;s COOLIEF beats steroid injections in treating osteoarthritis-related knee pain; shares ahead 2%</a></h4><ul><li>A clinical study evaluating Halyard Health's (HYH <font color='green'>+1.6%</font>) COOLIEF Cooled Radiofrequency &#40;RF&#41; for the treatment of chronic osteoarthritis knee pain <a href=\"https://seekingalpha.com/pr/16943035-halyard-health-announces-new-data-supporting-coolief-cooled-rf-treatment-chronic\" target=\"_blank\">demonstrated</a> its superiority over intra-articular steroid injections at months 6 and 12. The results were presented at the European Society of Regional Anesthesia &amp; Pain Therapy in Lugano, Switzerland.</li><li>Data from the 151-subject study showed 74.1% of the patients in the COOLIEF group experienced a 50% reduction in pain at month 6, while 65.4% maintained the 50% reduction at month 12.</li><li>At baseline, 67.1% of the COOLIEF group and 62.7% of the steroid injection group reported symptoms of severe arthritis. At month 6, the portions were 5.2% and 37.3%, respectively. At month 12, the proportion in the cooled RF group increased slightly to 11.5%.</li><li>COOLIEF, cleared by the FDA in April, is a minimally invasive non-surgical procedure to target and treat nerves causing pain.</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/ANIK' title='Anika Therapeutics Inc.'>ANIK</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='green'>+10.2%</font>)(<a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a> <font color='green'>+2.8%</font>)(<a href='https://seekingalpha.com/symbol/CYTX' title='Cytori Therapeutics Inc'>CYTX</a> <font color='green'>+11.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296095\" data-linked=\"Halyard&#39;s COOLIEF beats steroid injections in treating osteoarthritis-related knee pain; shares ahead 2%\" data-tweet=\"$AVNS $AVNS $ANIK - Halyard&#39;s COOLIEF beats steroid injections in treating osteoarthritis-related knee pain; shares ahead 2% https://seekingalpha.com/news/3296095-halyards-coolief-beats-steroid-injections-in-treating-osteoarthritis-related-knee-pain-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3296095-halyards-coolief-beats-steroid-injections-in-treating-osteoarthritis-related-knee-pain-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296094\" data-ts=\"1505754834\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296094-banks-lead-gains-rate-surge-continues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banks lead gains as rate surge continues</a></h4><ul><li>It was less than two weeks ago that the 10-year Treasury yield was threatening to dip below 2%. Up another three basis points today, it currently sits at 2.23%.</li><li>Appreciating the steeper yield curve are the country's lenders. The <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a> and <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> are each&nbsp;<font color='green'>up well over 1%</font>, while the <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> is&nbsp;<font color='green'>ahead 1%</font>. This vs. the S&amp;P 500's&nbsp;<font color='green'>0.2% advance</font>&nbsp;today.</li><li>On tap for this week is the FOMC's two-day policy meeting, at which no rate hike is expected (good for the yield curve), but the trimming of the central bank's balance sheet is to be announced (effect on bonds still being debated).</li><li>Alongside the policy announcement will be an update to the bank's economic outlook and updated \"dots\" showing the various outlooks for the Fed Funds rate.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Guggenheim S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/RWW' title='Oppenheimer Financials Sector Revenue ETF'>RWW</a>, <a href='https://seekingalpha.com/symbol/FAZZ' title='Direxion Daily Financial Bear 1x Shares ETF'>FAZZ</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a>, <a href='https://seekingalpha.com/symbol/FNCF' title='iShares Edge MSCI Multifactor Financials ETF'>FNCF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3296094\" data-linked=\"Banks lead gains as rate surge continues\" data-tweet=\"$KBE $KRE $XLF - Banks lead gains as rate surge continues https://seekingalpha.com/news/3296094-banks-lead-gains-rate-surge-continues?source=tweet\" data-url=\"https://seekingalpha.com/news/3296094-banks-lead-gains-rate-surge-continues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296091\" data-ts=\"1505754080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296091-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ENVA' title='Enova International, Inc.'>ENVA</a> <font color='green'>+12%</font>.<a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/XIN' title='Xinyuan Real Estate Co., Ltd.'>XIN</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FMAO' title='Farmers & Merchants Bancorp Inc.'>FMAO</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296091\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$FANH $ENVA $GROW - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3296091-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296091-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296092\" data-ts=\"1505753991\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/D\" target=\"_blank\">D</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296092-connecticut-senate-oks-aid-for-dominions-millstone-nuclear-plant\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Connecticut senate OKs aid for Dominion&#39;s Millstone nuclear plant</a></h4><ul>     <li>The Connecticut state senate voted on Friday to <a href=\"https://ctmirror.org/2017/09/15/millstone-bill-clears-the-senate-and-goes-to-house/\" target=\"_blank\">give new life</a> to Dominion Energy's (<a href='https://seekingalpha.com/symbol/D' title='Dominion Energy, Inc.'>D</a> <font color='red'>-1.4%</font>) Millstone nuclear station, approving legislation that would empower state officials to allow the facility to compete with other carbon-free sources of electricity, if deemed in the public interest.</li>     <li>Dominion has been arguing for two years that Millstone needs new rules for selling electricity to remain economically viable.</li>     <li>The bill still needs to be taken up by the Connecticut House, which failed to pass a similar bill <a href=\"https://seekingalpha.com/news/3272518-connecticut-fails-pass-bill-supporting-dominions-millstone-nuclear-plant\" target=\"_blank\">in June</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296092\" data-linked=\"Connecticut senate OKs aid for Dominion&#39;s Millstone nuclear plant\" data-tweet=\"$D - Connecticut senate OKs aid for Dominion&#39;s Millstone nuclear plant https://seekingalpha.com/news/3296092-connecticut-senate-oks-aid-for-dominions-millstone-nuclear-plant?source=tweet\" data-url=\"https://seekingalpha.com/news/3296092-connecticut-senate-oks-aid-for-dominions-millstone-nuclear-plant\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296084\" data-ts=\"1505753102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296084-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a> <font color='green'>+42%</font>. <a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/LOV' title='Spark Networks, Inc'>LOV</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/SSNI' title='Silver Spring Networks'>SSNI</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/OA' title='Orbital ATK, Inc.'>OA</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/VJET' title='voxeljet AG'>VJET</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/PZG' title='Paramount Gold Nevada Corp.'>PZG</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+16%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/UUU' title='Universal Security Instruments, Inc'>UUU</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/KALA' title='Kala Pharmaceuticals'>KALA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/QRHC' title='Quest Resource Holding Corp.'>QRHC</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ONS-OLD' title='Oncobiologics'>ONS-OLD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/KEYW' title='KEYW Holding'>KEYW</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/FMAO' title='Farmers & Merchants Bancorp Inc.'>FMAO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/AAN' title='Aaron&#39;s Inc.'>AAN</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296084\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$NBRV $DMTX $LOV - Midday Gainers / Losers https://seekingalpha.com/news/3296084-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3296084-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296083\" data-ts=\"1505752835\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBNT\" target=\"_blank\">UBNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296083-jmp-analyst-defends-ubiquiti-against-fraud-accusation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JMP analyst defends Ubiquiti against fraud accusation</a></h4><ul><li>        JMP analyst Erik Suppiger defends Ubiquiti Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/UBNT' title='Ubiquiti Networks, Inc.'>UBNT</a>) saying he &ldquo;does not see fraud&rdquo; as alleged by Citron Research this morning.</li><li>               Suppiger&rsquo;s comments came during a call with Bloomberg and the analyst continues that he sees the company as a &ldquo;well-established business with a pretty dominant brand name&rdquo; though he would like to &ldquo;take a closer look&rdquo; at the distribution model changes.&nbsp;</li><li>               Source: Bloomberg First Word&nbsp;</li><li>               Ubiquiti shares are&nbsp;<font color='red'>down 9.1%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296039-ubiquiti-networks-fraud-claims-citron-research\" target=\"_blank\">Ubiquiti Networks down on fraud claims from Citron Research</a> (Sept. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296083\" data-linked=\"JMP analyst defends Ubiquiti against fraud accusation\" data-tweet=\"$UBNT $UI - JMP analyst defends Ubiquiti against fraud accusation https://seekingalpha.com/news/3296083-jmp-analyst-defends-ubiquiti-against-fraud-accusation?source=tweet\" data-url=\"https://seekingalpha.com/news/3296083-jmp-analyst-defends-ubiquiti-against-fraud-accusation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296080\" data-ts=\"1505752316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296080-applied-optoelectronics-up-11_7-on-general-market-strength-short-covering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Optoelectronics up 11.7% on general market strength, short covering</a></h4><ul><li>Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) shares&nbsp;<font color='green'>up 11.73%</font>&nbsp;due to general optical component maker strength and the underway European Conference on Optical Communications.</li><li>Short interest as percentage of free float is 54%, which Bloomberg notes comes in second among tech companies with market caps over $100M.</li><li>Source: Bloomberg First Word</li><li>Correction: Title updated for clarity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296080\" data-linked=\"Applied Optoelectronics up 11.7% on general market strength, short covering\" data-tweet=\"$AAOI - Applied Optoelectronics up 11.7% on general market strength, short covering https://seekingalpha.com/news/3296080-applied-optoelectronics-up-11_7-on-general-market-strength-short-covering?source=tweet\" data-url=\"https://seekingalpha.com/news/3296080-applied-optoelectronics-up-11_7-on-general-market-strength-short-covering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>109&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296076\" data-ts=\"1505750897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMCI\" target=\"_blank\">SMCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296076-da-davidson-downgrades-super-micro-computer-shares-down-7_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DA Davidson downgrades Super Micro Computer; shares down 7.5%</a></h4><ul><li>        DA Davidson <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+DA+Davidson+Downgrades+Super+Micro+Computer+%28SMCI%29+to+Neutral/13303105.html\" target=\"_blank\">downgrades</a> Super Micro Computer (NASDAQ:<a href='https://seekingalpha.com/symbol/SMCI' title='Super Micro Computer, Inc.'>SMCI</a>) from Buy to Neutral and drops the price target from $33 to $27.</li><li>               Analyst Mark Kelleher cites uncertainty about the &ldquo;missing 10K&rdquo; that earned the company a noncompliance letter from Nasdaq last week.&nbsp;</li><li>                  Kelleher sees growths on the top and bottom lines but can&rsquo;t look beyond that 10K and accordingly steps to the side.    </li><li>               Super Micro Computer shares are&nbsp;<font color='red'>down 7.51%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295638-super-micro-computer-warned-nasdaq-late-10-k\" target=\"_blank\">Super Micro Computer warned by Nasdaq over late 10-K</a> (Sept. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296076\" data-linked=\"DA Davidson downgrades Super Micro Computer; shares down 7.5%\" data-tweet=\"$SMCI - DA Davidson downgrades Super Micro Computer; shares down 7.5% https://seekingalpha.com/news/3296076-da-davidson-downgrades-super-micro-computer-shares-down-7_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3296076-da-davidson-downgrades-super-micro-computer-shares-down-7_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296074\" data-ts=\"1505750532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALB\" target=\"_blank\">ALB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296074-albemarle-asks-to-increase-lithium-production-limit-in-chile\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Albemarle asks to increase lithium production limit in Chile</a></h4><ul>     <li>Albemarle (<a href='https://seekingalpha.com/symbol/ALB' title='Albemarle Corporation'>ALB</a> <font color='green'>+2.9%</font>) has asked Chile's government to allow it to <a href=\"http://www.reuters.com/article/chile-lithium-albemarle/albemarle-asks-chile-to-raise-lithium-production-limit-idUSL2N1LW1LP\" target=\"_blank\">raise its lithium production quota</a> to 125K metric tons/year from the current 80K tons/year limit.</li>     <li>ALB says new technology would allow it to obtain more lithium without needing to extract more brine out of the Atacama salt flat, which is part of the &ldquo;lithium triangle&rdquo; in Argentina, Bolivia and Chile that contains much of the world&rsquo;s reserves for the mineral used in batteries.</li>     <li>Lithium producers, including ALB, SQM (<a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='green'>+2.1%</font>) and FMC&nbsp;Corp. (<a href='https://seekingalpha.com/symbol/FMC' title='FMC Corporation'>FMC</a> <font color='green'>+2.2%</font>), as well as the Global X&nbsp;Lithium ETF (<a href='https://seekingalpha.com/symbol/LIT' title='Global X Lithium ETF'>LIT</a> <font color='green'>+2%</font>), continue their <a href=\"https://seekingalpha.com/news/3294673-lithium-producers-party-china-mulls-ban-fossil-fuel-vehicles\" target=\"_blank\">recent rally</a>, all posting new 52-week highs today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296074\" data-linked=\"Albemarle asks to increase lithium production limit in Chile\" data-tweet=\"$ALB $ALB $SQM - Albemarle asks to increase lithium production limit in Chile https://seekingalpha.com/news/3296074-albemarle-asks-to-increase-lithium-production-limit-in-chile?source=tweet\" data-url=\"https://seekingalpha.com/news/3296074-albemarle-asks-to-increase-lithium-production-limit-in-chile\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296073\" data-ts=\"1505750467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296073-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/UQM' title='UQM Technologies, Inc'>UQM</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/MTOR' title='Meritor, Inc.'>MTOR</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NC' title='NACCO Industries Inc.'>NC</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/JAKK' title='JAKKS Pacific, Inc.'>JAKK</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296073\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$ADOM $UQM $MTOR - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3296073-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296073-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296070\" data-ts=\"1505750206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDR\" target=\"_blank\">CLDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296070-cloudera-down-after-filing-for-common-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cloudera down after filing for common stock offering</a></h4><ul><li>        Cloudera (NYSE:<a href='https://seekingalpha.com/symbol/CLDR' title='Cloudera, Inc.'>CLDR</a>) shares&nbsp;<font color='red'>down 3.76%&nbsp;</font>following Friday&rsquo;s aftermarket<a href=\"https://www.reuters.com/article/brief-cloudera-files-for-offering-of-up/brief-cloudera-files-for-offering-of-up-to-175-mln-of-its-common-stock-idUSFWN1LW0NC\" target=\"_blank\"> filing</a> for an up to $175M common stock offering.&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294427-cloudera-acquires-ai-training-consultancy-company\" target=\"_blank\">Cloudera acquires AI training and consultancy company</a> (Sept. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296070\" data-linked=\"Cloudera down after filing for common stock offering\" data-tweet=\"$CLDR - Cloudera down after filing for common stock offering https://seekingalpha.com/news/3296070-cloudera-down-after-filing-for-common-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3296070-cloudera-down-after-filing-for-common-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296067\" data-ts=\"1505749771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSTG\" target=\"_blank\">NSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296067-nanostrings-hyb-seq-technology-able-to-perform-liquid-biopsy-measurements-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nanostring&#39;s Hyb &amp; Seq technology able to perform liquid biopsy measurements; shares ahead 2%</a></h4><ul><li>Thinly traded micro cap Nanostring Technologies (<a href='https://seekingalpha.com/symbol/NSTG' title='NanoString Technologies'>NSTG</a> <font color='green'>+1.5%</font>) perks up on average volume on the <a href=\"https://seekingalpha.com/pr/16942782-nanostring-s-hyb-and-seq-enables-liquid-biopsy-direct-capture-sequencing-cell-free-dna\" target=\"_blank\">news </a>that it demonstrated the capability of its Hyb &amp; Seq technology to perform liquid biopsies. The proof-of-principle work was presented at the Advances in Genome Biology and Technology Precision Health meeting in Scottsdale, AZ.</li><li><a href=\"https://www.nanostring.com/scientific-content/technology-overview/hyb-seq\" target=\"_blank\">Hyb &amp; Seq</a> is the company's single-molecule sequencing technology that it says is simpler, faster and more flexible than other offerings.</li><li>The oncology community is keenly interested in the concept of measuring cell-free DNA in the blood as a means to monitor (possibly to detect) cancer because it is more convenient, less costly and more patient-friendly than tissue biopsies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296067\" data-linked=\"Nanostring&#39;s Hyb &amp; Seq technology able to perform liquid biopsy measurements; shares ahead 2%\" data-tweet=\"$NSTG - Nanostring&#39;s Hyb &amp; Seq technology able to perform liquid biopsy measurements; shares ahead 2% https://seekingalpha.com/news/3296067-nanostrings-hyb-seq-technology-able-to-perform-liquid-biopsy-measurements-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3296067-nanostrings-hyb-seq-technology-able-to-perform-liquid-biopsy-measurements-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296066\" data-ts=\"1505749233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/S\" target=\"_blank\">S</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296066-sprint-improves-iphone-8-pre-order-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint improves iPhone 8 pre-order offer</a></h4><ul><li>        Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>) <a href=\"https://www.theverge.com/circuitbreaker/2017/9/18/16326842/sprint-iphone-8-preorder-deal-flex-lease-discount-trade-in-switching-customers\" target=\"_blank\">improves</a> its iPhone 8 pre-order offer to better compete with other carriers.</li><li>               Sprint now offers new customers a free 18-month lease when trading in an iPhone 7 or 7 Plus or a Samsung Galaxy S8, S8 Plus, or Note 8.&nbsp;</li><li>               Sprint will automatically upgrade qualified existing preorders to reflect this deal.&nbsp;</li><li>               Customers trading in an older phone, or existing customers, get Sprint&rsquo;s original offer of 50% off the lease.&nbsp;</li><li>Sprint shares are&nbsp;<font color='red'>down 1.17%</font>. &nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295799-oppenheimer-expects-wireless-promotions-heat\" target=\"_blank\">Oppenheimer expects wireless promotions to heat up</a> (Sept. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296066\" data-linked=\"Sprint improves iPhone 8 pre-order offer\" data-tweet=\"$S - Sprint improves iPhone 8 pre-order offer https://seekingalpha.com/news/3296066-sprint-improves-iphone-8-pre-order-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3296066-sprint-improves-iphone-8-pre-order-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296065\" data-ts=\"1505749165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296065-piper-jaffray-warns-on-finish-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray warns on Finish Line</a></h4><ul> <li>Finish Line (<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='red'>-4.4%</font>) trades lower after Piper Jaffray <a href=\"https://www.streetinsider.com/Analyst+Comments/Piper+Jaffray+Downgrades+Finish+Line+%28FINL%29+to+Underweight/13303038.html\" target=\"_blank\">drops</a> its rating to Underweight after having the retailer set at Neutral.</li> <li>Analyst Erinn Murpy notes that Finish Line has a high exposure to regions impacted by Hurricanes Harvey and Irma.</li> <li>Murphy thinks Finish Line's Q3 results will be under pressure due to the disruption. Her price target on FINL is lowered to $8 (20% downside).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296065\" data-linked=\"Piper Jaffray warns on Finish Line\" data-tweet=\"$FINL - Piper Jaffray warns on Finish Line https://seekingalpha.com/news/3296065-piper-jaffray-warns-on-finish-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3296065-piper-jaffray-warns-on-finish-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296061\" data-ts=\"1505748624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPR\" target=\"_blank\">CAPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296061-buying-ticks-up-in-capricor-therapeutics-ahead-of-six-month-data-on-dmd-candidate-capminus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buying ticks up in Capricor Therapeutics ahead of six-month data on DMD candidate CAP-1002; shares ahead 16%</a></h4><ul><li>Nano cap Capricor Therapeutics (<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+16%</font>) perks up modestly higher volume in early trading. Investors appear to be taking positions ahead of its <a href=\"https://seekingalpha.com/pr/16942884-capricor-therapeutics-present-six-month-results-randomized-hope-trial-capminus-1002-duchenne\" target=\"_blank\">presentation </a>of six-month data from the Phase 1/2 HOPE-Duchenne study evaluating CAP-1002. The results will be presented on October 4 in France at the International Congress of the World Muscle Society.</li><li><a href=\"http://capricor.com/product-pipeline/cap-1002/\" target=\"_blank\">CAP-1002</a>&nbsp;is an investigational allogeneic, off-the-shelf cardiac cell therapy derived from donor heart tissue and infused directly into the patient's coronary artery via a catheter.&nbsp;It is currently being evaluated for the treatment of heart disease associated with Duchenne muscular dystrophy and myocardial infarction (heart attack).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3282318-capricor-36-percent-clarity-regulatory-path-dmd-candidate-capminus-1002\" target=\"_blank\">Capricor up 36% on clarity of regulatory path for DMD candidate CAP-1002</a> (July 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296061\" data-linked=\"Buying ticks up in Capricor Therapeutics ahead of six-month data on DMD candidate CAP-1002; shares ahead 16%\" data-tweet=\"$CAPR - Buying ticks up in Capricor Therapeutics ahead of six-month data on DMD candidate CAP-1002; shares ahead 16% https://seekingalpha.com/news/3296061-buying-ticks-up-in-capricor-therapeutics-ahead-of-six-month-data-on-dmd-candidate-capminus?source=tweet\" data-url=\"https://seekingalpha.com/news/3296061-buying-ticks-up-in-capricor-therapeutics-ahead-of-six-month-data-on-dmd-candidate-capminus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296060\" data-ts=\"1505748566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOK\" target=\"_blank\">NOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296060-nokia-announces-patent-award-in-lg-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nokia announces patent award in LG case</a></h4><ul><li>Nokia (NYSE:<a href='https://seekingalpha.com/symbol/NOK' title='Nokia Corporation'>NOK</a>) <a href=\"https://www.reuters.com/article/nokia-patents-lg-elec/nokia-gets-decision-in-patent-arbitration-with-lg-idUSASO0000Y8\" target=\"_blank\">announces</a> receiving a patent decision in its arbitration with LG Electronics (<a href='https://seekingalpha.com/symbol/LGEAF' title='LG Electronics Inc.'>OTC:LGEAF</a>).</li><li>Nokia didn&rsquo;t disclose the award details but said it will book revenue and a non-recurring catch-up payment starting in Q3.</li><li>Nokia shares are&nbsp;<font color='green'>up 1.14%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294398-nokia-minus-2_1-percent-amid-index-removal-job-cuts-france\" target=\"_blank\">Nokia -2.1% amid index removal, job cuts in France</a> (Sept. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296060\" data-linked=\"Nokia announces patent award in LG case\" data-tweet=\"$NOK $NOK $LGEAF - Nokia announces patent award in LG case https://seekingalpha.com/news/3296060-nokia-announces-patent-award-in-lg-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3296060-nokia-announces-patent-award-in-lg-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296058\" data-ts=\"1505747750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296058-boes-carney-reiterates-case-for-rate-rise-pound-tumbles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BOE&#39;s Carney reiterates case for rate rise; pound tumbles</a></h4><ul><li>Here's a good one: Brexit is crimping capacity in the U.K., says <a href=\"http://www.bankofengland.co.uk/publications/Documents/speeches/2017/speech996.pdf\" target=\"_blank\">Bank of England Governor Mark Carney</a>, meaning economic growth is more likely to lead to inflation, thus boosting the case for rate hikes.</li><li>A year ago, the surprise Brexit vote had the Bank quickly pushing into place emergency stimulus measures.</li><li>Thoroughly confused at this point, forex traders are selling cable, with the pound now<font color='red'> lower by 0.5%</font>&nbsp;vs. the dollar at $1.3513 (though this is coming after more than a&nbsp;<font color='green'>5% gain&nbsp;</font>over the past three weeks).</li><li>The FTSE 100 is&nbsp;<font color='green'>up 0.35%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/FXB' title='CurrencyShares British Pound Sterling Trust ETF'>FXB</a>, <a href='https://seekingalpha.com/symbol/EWU' title='iShares MSCI United Kingdom ETF'>EWU</a>, <a href='https://seekingalpha.com/symbol/GBB' title='iPath GBP/USD Exchange Rate ETN'>GBB</a>, <a href='https://seekingalpha.com/symbol/DBUK' title='Deutsche X-trackers MSCI United Kingdom Hedged Equity ETF'>DBUK</a>, <a href='https://seekingalpha.com/symbol/FKU' title='First Trust United Kingdom AlphaDex ETF'>FKU</a>, <a href='https://seekingalpha.com/symbol/EWUS' title='iShares MSCI United Kingdom Small Cap Index ETF'>EWUS</a>, <a href='https://seekingalpha.com/symbol/DXPS' title='WisdomTree United Kingdom Hedged Equity ETF'>DXPS</a>, <a href='https://seekingalpha.com/symbol/HEWU' title='iShares Currency Hedged MSCI United Kingdom ETF'>HEWU</a>, <a href='https://seekingalpha.com/symbol/QGBR' title='SPDR MSCI United Kingdom Quality Mix ETF'>QGBR</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3296058\" data-linked=\"BOE&#39;s Carney reiterates case for rate rise; pound tumbles\" data-tweet=\"$FXB $EWU $GBB - BOE&#39;s Carney reiterates case for rate rise; pound tumbles https://seekingalpha.com/news/3296058-boes-carney-reiterates-case-for-rate-rise-pound-tumbles?source=tweet\" data-url=\"https://seekingalpha.com/news/3296058-boes-carney-reiterates-case-for-rate-rise-pound-tumbles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296057\" data-ts=\"1505747668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOLD\" target=\"_blank\">GOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296057-gold-prices-sink-dollar-strengthens\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold prices sink as dollar strengthens</a></h4><ul>     <li>Precious metals are on track for their <a href=\"https://www.wsj.com/articles/metals-gold-prices-retreat-as-dollar-strengthens-1505745019\" target=\"_blank\">fifth day of losses in the past six sessions</a>, hurt by a stronger dollar; Comex gold currently <font color='red'>-1%</font> at $1,312.20/oz., its lowest since August, silver <font color='red'>-2.2%</font> at $17.31/oz.</li>     <li>Markets have shaken off geopolitical turbulence in recent sessions, sending stocks to new records and hurting gold and other haven assets; and &rdquo;the stronger dollar and stronger Treasury yields will continue to put pressure&rdquo; on precious metals, says Walter Pehowich, Senior VP at Dillon Gage Metals.</li>     <li>Gold bugs also will be watching this week&rsquo;s FOMC meeting, in which the Fed is not seen raising interest rates but likely offering clues about how aggressive it could be in moving forward with balance sheet tapering.</li><li>Among major precious metals miners: ABX <font color='red'>-1.6%</font>, <a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a> <font color='red'>-2.1%</font>, <a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a> <font color='red'>-0.2%</font>, <a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a> <font color='red'>-5.6%</font>, <a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='green'>+0.4%</font>, <a href='https://seekingalpha.com/symbol/AEM' title='Agnico Eagle Mines Limited'>AEM</a> <font color='red'>-2.8%</font>, <a href='https://seekingalpha.com/symbol/RGLD' title='Royal Gold, Inc.'>RGLD</a> flat, <a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color='red'>-3.3%</font>, <a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='red'>-7%</font>, <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='red'>-5.2%</font>, <a href='https://seekingalpha.com/symbol/GFI' title='Gold Fields Limited'>GFI</a> <font color='red'>-2.7%</font>, <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-4.1%</font>, <a href='https://seekingalpha.com/symbol/AG' title='First Majestic Silver Corp.'>AG</a> <font color='red'>-2.5%</font>, <a href='https://seekingalpha.com/symbol/WPM' title='Wheaton Precious Metals Corp'>WPM</a> <font color='red'>-3.1%</font>, <a href='https://seekingalpha.com/symbol/PAAS' title='Pan American Silver Corp.'>PAAS</a> <font color='red'>-1.4%</font>, <a href='https://seekingalpha.com/symbol/HL' title='Hecla Mining Co.'>HL</a> <font color='red'>-0.4%</font>.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/SLV' title='iShares Silver Trust ETF'>SLV</a>, <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a>, <a href='https://seekingalpha.com/symbol/NUGT' title='Direxion Daily Gold Miners Index Bull 3x Shares ETF'>NUGT</a>, <a href='https://seekingalpha.com/symbol/GGN' title='GAMCO Global Gold, Natural Resources & Income Trust'>GGN</a>, <a href='https://seekingalpha.com/symbol/DUST' title='Direxion Daily Gold Miners Index Bear 3x Shares ETF'>DUST</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/AGQ' title='ProShares Ultra Silver ETF'>AGQ</a>, <a href='https://seekingalpha.com/symbol/PSLV' title='Sprott Physical Silver Trust'>PSLV</a>, <a href='https://seekingalpha.com/symbol/SIL' title='Global X Silver Miners ETF'>SIL</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/USLV' title='VelocityShares 3x Long Silver ETN'>USLV</a>, <a href='https://seekingalpha.com/symbol/SIVR' title='Aberd Std Silvr Shs'>SIVR</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='Aberdn Std Gold Shs'>SGOL</a>, <a href='https://seekingalpha.com/symbol/GOEX' title='Global X Gold Explorers ETF'>GOEX</a>, <a href='https://seekingalpha.com/symbol/ZSL' title='ProShares UltraShort Silver ETF'>ZSL</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/SGDM' title='Sprott Gold Miners ETF'>SGDM</a>, <a href='https://seekingalpha.com/symbol/SLVO' title='Credit Suisse Silver Shares Covered Call ETN'>SLVO</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/GTU' title='Central Gold-Trust'>GTU</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/ASA' title='ASA Gold&Precious Metals'>ASA</a>, <a href='https://seekingalpha.com/symbol/SLVP' title='iShares MSCI Global Silver Miners ETF'>SLVP</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/DSLV' title='VelocityShares 3x Inverse Silver ETN'>DSLV</a>, <a href='https://seekingalpha.com/symbol/RING' title='iShares MSCI Global Gold Miners ETF'>RING</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/DGL' title='Inv DB Mul-Sec Shs Invesco DB Gold Fund'>DGL</a>, <a href='https://seekingalpha.com/symbol/TGLDX' title='Tocqueville Gold Fund No Load'>TGLDX</a>, <a href='https://seekingalpha.com/symbol/DBS' title='Invesco DB Silver ETF'>DBS</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/PSAU' title='Invesco Global Gold and Precious Metals Portfolio ETF'>PSAU</a>, <a href='https://seekingalpha.com/symbol/GDXX' title='ProShares Ultra Gold Miners ETF'>GDXX</a>, <a href='https://seekingalpha.com/symbol/GYEN' title='AdvisorShares Gartman Gold/Yen ETF'>GYEN</a>, <a href='https://seekingalpha.com/symbol/GEUR' title='AdvisorShares Gartman Gold/Euro ETF'>GEUR</a>, <a href='https://seekingalpha.com/symbol/GLDW' title='SPDR Long Dollar Gold Trust ETF'>GLDW</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/GDXS' title='ProShares UltraShort Gold Miners ETF'>GDXS</a>, <a href='https://seekingalpha.com/symbol/USV' title='UBS ETRACS CMCI Silver Total Return ETN'>USV</a>, <a href='https://seekingalpha.com/symbol/GHS' title='REX Gold Hedged S&P 500 ETF'>GHS</a>, <a href='https://seekingalpha.com/symbol/SHNY' title='Direxion Daily Silver Miners Index Bull 2x Shares ETF'>SHNY</a>, <a href='https://seekingalpha.com/symbol/MELT' title='Direxion Daily Gold Miners Index Bear 1x Shares ETF'>MELT</a>, <a href='https://seekingalpha.com/symbol/GHE' title='REX Gold Hedged FTSE Emerging Markets ETF'>GHE</a>, <a href='https://seekingalpha.com/symbol/DULL' title='Direxion Daily Silver Miners Index Bear 2x Shares ETF'>DULL</a>, <a href='https://seekingalpha.com/symbol/QGLDX' title='The Gold Bullion Strategy Fund Inv'>QGLDX</a>, <a href='https://seekingalpha.com/symbol/GOAU' title='U.S. Global GO GOLD and Precious Metal Miners ETF'>GOAU</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3296057\" data-linked=\"Gold prices sink as dollar strengthens\" data-tweet=\"$GOLD $GOLD $GG - Gold prices sink as dollar strengthens https://seekingalpha.com/news/3296057-gold-prices-sink-dollar-strengthens?source=tweet\" data-url=\"https://seekingalpha.com/news/3296057-gold-prices-sink-dollar-strengthens\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296055\" data-ts=\"1505747019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RYAAY\" target=\"_blank\">RYAAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296055-pilot-issues-mount-ryanair\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pilot issues mount at Ryanair</a></h4><ul> <li>The European Commission <a href=\"https://www.ft.com/content/31a4b6aa-a3da-314f-b578-aca77b27a6a6\" target=\"_blank\">warns</a> Ryanair (NASDAQ:<a href='https://seekingalpha.com/symbol/RYAAY' title='Ryanair Holdings PLC'>RYAAY</a>) that it be may be fined for canceling a large number of flights in the next six weeks due to pilot labor issues.</li><li>The airline canceled the flights due to a wave of employees taking holidays at the same time.</li> <li>\"Airlines operating in the EU need to respect the European rules... Passengers whose flights are cancelled have a comprehensive set of rights,\" says an EC spokesman.</li> <li>Shares of Ryanair are <font color='red'>down 1.25%</font> in London. Ryanair ADRs are <font color='red'>down 0.60%</font> on the day.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296055\" data-linked=\"Pilot issues mount at Ryanair\" data-tweet=\"$RYAAY - Pilot issues mount at Ryanair https://seekingalpha.com/news/3296055-pilot-issues-mount-ryanair?source=tweet\" data-url=\"https://seekingalpha.com/news/3296055-pilot-issues-mount-ryanair\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296054\" data-ts=\"1505746961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LORL\" target=\"_blank\">LORL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296054-checking-aviation-names-after-northrop-orbital-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Checking aviation names after Northrop/Orbital deal</a></h4><ul><li>Possible targets: Loral (<a href='https://seekingalpha.com/symbol/LORL' title='Loral Space and Communications, Inc.'>LORL</a> <font color='green'>+3.5%</font>), Aerojet Rocketdyne Holdings (<a href='https://seekingalpha.com/symbol/AJRD' title='Aerojet Rocketdyne Holdings, Inc'>AJRD</a> <font color='green'>+7.4%</font>), L3 Technologies (<a href='https://seekingalpha.com/symbol/LLL' title='L3 Technologies'>LLL</a> <font color='red'>-0.1%</font>), BAE Systems (<a href='https://seekingalpha.com/symbol/BAESY' title='BAE Systems PLC ADR'>OTCPK:BAESY</a> <font color='green'>+3.6%</font>)</li><li>Possible acquirers: Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='green'>+1.1%</font>), Raytheon (<a href='https://seekingalpha.com/symbol/RTN' title='Raytheon Company'>RTN</a> flat), General Dynamics (<a href='https://seekingalpha.com/symbol/GD' title='General Dynamics Corporation'>GD</a> <font color='green'>+1.1%</font>), Lockheed Martin (<a href='https://seekingalpha.com/symbol/LMT' title='Lockheed Martin'>LMT</a> <font color='green'>+0.3%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295940-northrop-buy-orbital-atk-9_2b\" target=\"_blank\">Northrop to buy Orbital ATK for $9.2B</a> (Sept. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296054\" data-linked=\"Checking aviation names after Northrop/Orbital deal\" data-tweet=\"$LORL $LORL $AJRD - Checking aviation names after Northrop/Orbital deal https://seekingalpha.com/news/3296054-checking-aviation-names-after-northrop-orbital-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3296054-checking-aviation-names-after-northrop-orbital-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296028\" data-ts=\"1505746886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296028-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a> <font color='green'>+60%</font>. NRCIA <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/QDEL' title='Quidel Corporation'>QDEL</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/PGNX' title='Progenics Pharmaceuticals Inc.'>PGNX</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/ONS-OLD' title='Oncobiologics'>ONS-OLD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/APHB' title='AmpliPhi Biosciences Corp.'>APHB</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/NEOS' title='Neos Therapeutics'>NEOS</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296028\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$NBRV $NRC $QDEL - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3296028-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3296028-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296052\" data-ts=\"1505746612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GFASY\" target=\"_blank\">GFASY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296052-gafisa-on-move\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gafisa on the move</a></h4><ul><li>Option delistings effective today include Gafisa (GFA). The stock is <font color='green'>up 7.5%</font> to start the week.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296052\" data-linked=\"Gafisa on the move\" data-tweet=\"$GFASY - Gafisa on the move https://seekingalpha.com/news/3296052-gafisa-on-move?source=tweet\" data-url=\"https://seekingalpha.com/news/3296052-gafisa-on-move\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296045\" data-ts=\"1505745902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BEAT\" target=\"_blank\">BEAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296045-selloff-in-biotelemetry-unfounded-dougherty-shares-down-18-since-last-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Selloff in BioTelemetry unfounded - Dougherty; shares down 18% since last week</a></h4><ul><li>Dougherty reiterates its Buy opinion on BioTelemetry (<a href='https://seekingalpha.com/symbol/BEAT' title='BioTelemetry, Inc.'>BEAT</a> <font color='red'>-4.3%</font>) trying to stem the selling after Off Wall Street <a href=\"https://stocknewstimes.com/2017/09/18/biotelemetry-inc-beat-research-coverage-started-at-off-wall-street.html\" target=\"_blank\">published </a>a research report with Sell rating and $21 (34% downside risk) price target. Shares were down as much as&nbsp;<font color='red'>8%</font>&nbsp;today before recovering, but they are still off 18% since last week.</li><li>Dougherty acknowledges that BEAT's revenue has slowed, but says a 1% reimbursement cut by CMS created temporary headwinds that should be eliminated if a 2% increase is approved for 2018 as indicated in a preliminary ruling in July. The increase should help the company achieve 10% top line growth next year, a level viewed as unrealistic by OWS.</li><li>BEAT's H1 revenues were $114.0M, up 12.5% while Q2's top line was up 10.2% to $58.1M. Last month, management raised revenue guidance to $285M - 290M.</li><li>Principal source: Bloomberg. Q2 and H1 numbers from BEAT Q2 earnings&nbsp;<a href=\"https://seekingalpha.com/pr/16910447-biotelemetry-inc-reports-second-quarter-2017-financial-results\" target=\"_blank\">press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296045\" data-linked=\"Selloff in BioTelemetry unfounded - Dougherty; shares down 18% since last week\" data-tweet=\"$BEAT - Selloff in BioTelemetry unfounded - Dougherty; shares down 18% since last week https://seekingalpha.com/news/3296045-selloff-in-biotelemetry-unfounded-dougherty-shares-down-18-since-last-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3296045-selloff-in-biotelemetry-unfounded-dougherty-shares-down-18-since-last-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296048\" data-ts=\"1505745837\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296048-evercore-raises-micron-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evercore raises Micron price target</a></h4><ul><li>        Evercore ISI <a href=\"https://www.streetinsider.com/Analyst+Comments/Micron+Technology+%28MU%29+PT+Raised+to+%2450+at+Evercore+ISI+Into+Results/13303990.html\" target=\"_blank\">raises</a> its Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) price target by $10 to $50 and maintains an Outperform rating.</li><li>               Analyst C.J. Muse sees the current DRAM cycle as sustainable due to improving demand paired with acceleration in storage and processing, constricted supplies due to rising complexity, and bit growth reduction due to shrinks.&nbsp;</li><li>               Muse forecasts Micron reporting FY17 EPS at $5, compared to $0.25 in FY16, and FCF at $2.6B, compared to a matching loss last year. CY18 estimates put EPS at $7.20 and FCF per share at $5.&nbsp;</li><li>               DRAM supply constriction through CY18 will push DRAM capex up 15% to 20%.&nbsp;</li><li>               Micron shares are&nbsp;<font color='green'>up 2.35%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3296048\" data-linked=\"Evercore raises Micron price target\" data-tweet=\"$MU - Evercore raises Micron price target https://seekingalpha.com/news/3296048-evercore-raises-micron-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3296048-evercore-raises-micron-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>70&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296042\" data-ts=\"1505744716\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296042-rumor-himax-to-announce-150m-auto-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rumor: Himax to announce $150M auto deal</a></h4><ul><li>        Himax Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>) shares&nbsp;<font color='green'>up 2.08%</font>&nbsp;on rumors that the company will soon announce a $150M auto deal, per Marc Lehman&rsquo;s <a href=\"https://twitter.com/markflowchatter/status/909772933094166528\" target=\"_blank\">Twitter</a>.</li><li>               Will update with more information when the deal is announced.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3296042\" data-linked=\"Rumor: Himax to announce $150M auto deal\" data-tweet=\"$HIMX - Rumor: Himax to announce $150M auto deal https://seekingalpha.com/news/3296042-rumor-himax-to-announce-150m-auto-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3296042-rumor-himax-to-announce-150m-auto-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>103&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296041\" data-ts=\"1505744626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSIQ\" target=\"_blank\">CSIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296041-eu-to-lower-minimum-prices-on-imported-chinese-solar-panels\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EU to lower minimum prices on imported Chinese solar panels</a></h4><ul>     <li>China&rsquo;s Ministry of Commerce praises the European Union's weekend decision to <a href=\"https://uk.reuters.com/article/uk-china-eu-anti-dumping/china-welcomes-eu-decision-on-solar-panel-import-prices-idUKKCN1BT0Q4\" target=\"_blank\">lower the minimum price</a> imposed on imported Chinese solar panels and hopes duties will end as soon as possible.</li>     <li>The EU announced on Sept. 16 that it would progressively reduce the minimum prices that Chinese solar panel makers are allowed to sell their products for in Europe, allowing price cuts every three months beginning Oct. 1 and wrapping up on July 1 next year; Chinese companies that sell below the minimum prices are subject to import duties of up to 64.9%.</li><li>Relevant tickers: <a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='green'>+0.8%</font>, <a href='https://seekingalpha.com/symbol/JASO' title='JA Solar Holdings, Co., Ltd.'>JASO</a> <font color='green'>+3.6%</font>, <a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/TSL' title='Trina Solar Limited'>TSL</a> flat, <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-0.4%</font>, <a href='https://seekingalpha.com/symbol/SOL' title='ReneSola Ltd.'>SOL</a> <font color='red'>-0.4%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/TAN' title='Invesco Solar Portfolio ETF'>TAN</a>, <a href='https://seekingalpha.com/symbol/KWT' title='VanEck Vectors Solar Energy ETF'>KWT</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3296041\" data-linked=\"EU to lower minimum prices on imported Chinese solar panels\" data-tweet=\"$CSIQ $CSIQ $JASO - EU to lower minimum prices on imported Chinese solar panels https://seekingalpha.com/news/3296041-eu-to-lower-minimum-prices-on-imported-chinese-solar-panels?source=tweet\" data-url=\"https://seekingalpha.com/news/3296041-eu-to-lower-minimum-prices-on-imported-chinese-solar-panels\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296039\" data-ts=\"1505744363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBNT\" target=\"_blank\">UBNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296039-ubiquiti-networks-down-on-fraud-claims-from-citron-research\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ubiquiti Networks down on fraud claims from Citron Research</a></h4><ul><li>Ubiquiti Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/UBNT' title='Ubiquiti Networks, Inc.'>UBNT</a>) shares&nbsp;<font color='red'>down 6.25%&nbsp;</font>after Citron Research <a href=\"https://twitter.com/CitronResearch/status/909775549219794944\" target=\"_blank\">tweets</a>, &ldquo;Believe total FRAUD. All claims supported by fact. Not seen anything like this in YEARS.&rdquo;</li><li>Citron Research&rsquo;s accompanying <a href=\"http://www.citronresearch.com/citron-exposes-ubiquiti-networks/\" target=\"_blank\">report</a> outlines its case for the fraud claims and features &ldquo;red flags&rdquo; including the CEO using a fraud &ldquo;death word&rdquo; by saying people have misunderstood the company, operating metrics the firm finds questionable, and what Citron calls &ldquo;shady distributors&rdquo;.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285339-ubiquiti-networks-plus-24-percent-new-high-record-revenues\" target=\"_blank\">Ubiquiti Networks +24% to new high after record revenues</a> (Aug. 3)</li><li>Update:&nbsp;                  Ubiquiti CEO Robert J. Pera responds to Citron Research&rsquo;s claims on <a href=\"https://twitter.com/RobertPera/status/909784361402343425\" target=\"_blank\">Twitter</a>: &ldquo;I just put my head down and let the products and numbers speak for themselves. My apologies to those affected by these clowns.&rdquo;</li></ul><div class=\"tiny-share-widget\" data-id=\"3296039\" data-linked=\"Ubiquiti Networks down on fraud claims from Citron Research\" data-tweet=\"$UBNT $UI - Ubiquiti Networks down on fraud claims from Citron Research https://seekingalpha.com/news/3296039-ubiquiti-networks-down-on-fraud-claims-from-citron-research?source=tweet\" data-url=\"https://seekingalpha.com/news/3296039-ubiquiti-networks-down-on-fraud-claims-from-citron-research\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296038\" data-ts=\"1505744340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296038-takeover-rumor-du-jour-clovis-lilly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Takeover rumor du jour: Clovis by Lilly</a></h4><ul><li>Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='green'>+6.1%</font>) perks up on light volume amidst chatter that Eli Lilly (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='red'>-0.3%</font>) is mulling a bid.</li><li>The company recently announced positive results from a late-stage study assessing lead asset rucaparib in ovarian cancer.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294365-clovis-rucaparib-successful-late-stage-ovarian-cancer-study-shares-ahead-5-percent-premarket\" target=\"_blank\">Clovis' rucaparib successful in late-stage ovarian cancer study; shares ahead 5% premarket</a> (Sept. 8)</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3296038\" data-linked=\"Takeover rumor du jour: Clovis by Lilly\" data-tweet=\"$CLVS $CLVS $LLY - Takeover rumor du jour: Clovis by Lilly https://seekingalpha.com/news/3296038-takeover-rumor-du-jour-clovis-lilly?source=tweet\" data-url=\"https://seekingalpha.com/news/3296038-takeover-rumor-du-jour-clovis-lilly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296036\" data-ts=\"1505744016\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAN\" target=\"_blank\">AAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296036-aarons-lower-after-bear-call-from-off-wall-street\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AAron&#39;s lower after bear call from Off Wall Street</a></h4><ul> <li>Aaron's (<a href='https://seekingalpha.com/symbol/AAN' title='Aaron&#39;s Inc.'>AAN</a> <font color='red'>-6%</font>) heads lower after <a href=\"http://www.offwallstreet.com/ideas/\" target=\"_blank\">Off Wall Street</a> slaps a Sell rating on the retailer.</li> <li>The firm assigns a price target of $30 on Aaron's to rep more than 25% downside action.</li> <li>Shares of Aaron's have ranged from $22.37 to $48.22 over the last 52 weeks.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296036\" data-linked=\"AAron&#39;s lower after bear call from Off Wall Street\" data-tweet=\"$AAN - AAron&#39;s lower after bear call from Off Wall Street https://seekingalpha.com/news/3296036-aarons-lower-after-bear-call-from-off-wall-street?source=tweet\" data-url=\"https://seekingalpha.com/news/3296036-aarons-lower-after-bear-call-from-off-wall-street\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296035\" data-ts=\"1505743858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RARE\" target=\"_blank\">RARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296035-ultragenyx-makes-138m-cash-offer-for-dimension-therapeutics-trumps-regenxbios-all-stock-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ultragenyx makes $138M cash offer for Dimension Therapeutics, trumps REGENXBIO&#39;s all-stock deal</a></h4><ul><li>Ultragenyx Pharmaceutical (<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a> <font color='red'>-0.5%</font>) <a href=\"https://seekingalpha.com/pr/16943148-ultragenyx-proposes-acquire-dimension-therapeutics-5_50-per-share-cash\" target=\"_blank\">one-ups</a> REGENXBIO (<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a> <font color='green'>+1.6%</font>) with its $138M cash offer ($5.50 per share) for Dimension Therapeutics (<a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a>). RARE's bid represents a 31% premium over DMTX's Friday close of $4.20 and a 61% premium of RGNX's offer announced on August 25.</li><li>RARE will host a conference call today at 10:30 am ET to discuss the bid.</li><li>Trading in DMTX is currently suspended.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291791-regenxbio-acquire-dimension-therapeutics-stock-deal-dimension-163-percent-premarket\" target=\"_blank\">REGENXBIO to acquire Dimension Therapeutics in all-stock deal, Dimension up 163% premarket</a> (Aug. 25)</li><li><strong>Update</strong>: DMTX is up&nbsp;<font color='green'>31%</font>&nbsp;two hours into the session.</li><li><strong>Update</strong>: DMTX <a href=\"https://seekingalpha.com/pr/16943748-dimension-confirms-receipt-unsolicited-proposal-ultragenyx\" target=\"_blank\">confirms the receipt</a> of RARE's unsolicited proposal and intends to \"carefully review and consider\" the bid.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296035\" data-linked=\"Ultragenyx makes $138M cash offer for Dimension Therapeutics, trumps REGENXBIO&#39;s all-stock deal\" data-tweet=\"$RARE $RARE $RGNX - Ultragenyx makes $138M cash offer for Dimension Therapeutics, trumps REGENXBIO&#39;s all-stock deal https://seekingalpha.com/news/3296035-ultragenyx-makes-138m-cash-offer-for-dimension-therapeutics-trumps-regenxbios-all-stock-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3296035-ultragenyx-makes-138m-cash-offer-for-dimension-therapeutics-trumps-regenxbios-all-stock-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296032\" data-ts=\"1505743410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAT\" target=\"_blank\">MAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296032-toy-stocks-stumble-on-toys-r-us-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toy stocks stumble on Toys &quot;R&quot; Us concerns</a></h4><ul> <li>Toy stocks are lower as more warnings on a Toys \"R\" Us bankrupcty circulate.</li> <li>Stifel Nicolaus is front and center with a note to clients in which it discusses the negative impact on the sector of a bankrupcty filing ahead of the critical holiday season.</li> <li>Mattel (<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a> <font color='red'>-1.5%</font>), Hasbro (<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a> <font color='red'>-1.3%</font>) and JAKKS Pacific (<a href='https://seekingalpha.com/symbol/JAKK' title='JAKKS Pacific, Inc.'>JAKK</a> <font color='red'>-1.6%</font>) are all lower in early trading.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295674-high-anxiety-toys-r-us-suppliers\" target=\"_blank\">High anxiety for Toys \"R\" Us suppliers</a> (Sept. 15)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295908-toys-r-us-preps-bankruptcy-filing\" target=\"_blank\">Toys 'R' Us preps bankruptcy filing</a> (Sept. 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296032\" data-linked=\"Toy stocks stumble on Toys &quot;R&quot; Us concerns\" data-tweet=\"$MAT $MAT $HAS - Toy stocks stumble on Toys &quot;R&quot; Us concerns https://seekingalpha.com/news/3296032-toy-stocks-stumble-on-toys-r-us-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3296032-toy-stocks-stumble-on-toys-r-us-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296031\" data-ts=\"1505743334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SJI\" target=\"_blank\">SJI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296031-south-jersey-industries-downgraded-williams-on-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">South Jersey Industries downgraded at Williams on valuation</a></h4><ul>     <li>South Jersey Industries (<a href='https://seekingalpha.com/symbol/SJI' title='South Jersey Industries Inc.'>SJI</a> <font color='red'>-2.3%</font>) is <a href=\"https://www.streetinsider.com/Analyst+Comments/Williams+Capital+Downgrades+South+Jersey+Industries%2C+Inc.+%28SJI%29+to+Hold/13303327.html\" target=\"_blank\">downgraded</a> to Hold from Buy at Williams Capital after exceeding the firm's $36 stock price target.</li>     <li>\"While we like SJI&rsquo;s fundamental position, we find the stock near full value,\" Williams writes, also suggesting SJI shares ought to discount some risk in the PennEast pipeline project.</li>     <li>Williams maintains SJI's $36 price target, reflecting P/E valuation of 22.2x recurring 2019 EPS estimate, which the firm believes is \"more than generous.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296031\" data-linked=\"South Jersey Industries downgraded at Williams on valuation\" data-tweet=\"$SJI - South Jersey Industries downgraded at Williams on valuation https://seekingalpha.com/news/3296031-south-jersey-industries-downgraded-williams-on-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3296031-south-jersey-industries-downgraded-williams-on-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296021\" data-ts=\"1505741791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCO\" target=\"_blank\">TCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296021-taubman-cut-to-underweight-morgan-stanley-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Taubman cut to Underweight at Morgan Stanley; shares down 2%</a></h4><ul><li>Taubman Centers (NYSE:<a href='https://seekingalpha.com/symbol/TCO' title='Taubman Centers, Inc.'>TCO</a>) is the only class A REIT expected to report negative same-store sales growth in H2, says analyst Richard Hill. This should have investors turning their focus to the company's lagging free cash flow.</li><li>Tabuman, he says, faces more execution risk than peers as it attempts to stabilize three Asian malls. Its smaller portfolio could give it less negotiating leverage with retailers.</li><li>He cuts to Underweight, with the price target shaved to $47 from $56.</li><li>Shares&nbsp;<font color='red'>down 2.1%</font>&nbsp;to $51.40.</li><li>Source: Bloomberg's Catherine Larkin</li></ul><div class=\"tiny-share-widget\" data-id=\"3296021\" data-linked=\"Taubman cut to Underweight at Morgan Stanley; shares down 2%\" data-tweet=\"$TCO - Taubman cut to Underweight at Morgan Stanley; shares down 2% https://seekingalpha.com/news/3296021-taubman-cut-to-underweight-morgan-stanley-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3296021-taubman-cut-to-underweight-morgan-stanley-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296013\" data-ts=\"1505740559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296013-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a> <font color='green'>+92%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3295964-nabrivas-lefamulin-successful-late-stage-cabp-study-shares-ahead-92-percent-premarket\" target=\"_blank\">successful</a> in late-stage CABP study.</li>     <li><a href='https://seekingalpha.com/symbol/SSNI' title='Silver Spring Networks'>SSNI</a> <font color='green'>+25%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3296003-silver-springs-networks-bought-itron-shares-25-percent\" target=\"_blank\">bought</a> by Itron.</li>     <li><a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a> <font color='green'>+20%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16942865-u-s-fda-grants-fast-track-designation-pluristems-plx-pad-treatment-critical-limb-ischemia-cli\" target=\"_blank\">announcement</a> that the FDA has granted Fast Track Designation to the ongoing Phase III study of PLX-PAD cells for the treatment of Critical Limb Ischemia in patients ineligible for revascularization.</li>     <li><a href='https://seekingalpha.com/symbol/OA' title='Orbital ATK, Inc.'>OA</a> <font color='green'>+20%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3295940-northrop-buy-orbital-atk-9_2b\" target=\"_blank\">acquired</a> by&nbsp;Northrop&nbsp;for $9.2B.</li>     <li><a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3296007-pain-therapeutics-nabs-2_2m-nida-grant-shares-ahead-12-percent-premarket\" target=\"_blank\">nabbing</a> $2.2M NIDA grant.</li>     <li><a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3295982-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/BLDP' title='Ballard Power Systems, Inc.'>BLDP</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3295951-ballard-gets-purchase-order-nisshinbo\" target=\"_blank\">purchase order</a> from Nisshinbo.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296013\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$NBRV $SSNI $PSTI - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3296013-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3296013-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296012\" data-ts=\"1505740507\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTI\" target=\"_blank\">PSTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296012-pluristems-plx-pad-fast-trackd-for-critical-limb-ischemia-shares-ahead-20-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pluristem&#39;s PLX-PAD Fast Track&#39;d for critical limb ischemia; shares ahead 20% premarket</a></h4><ul><li>Thinly traded micro cap Pluristem Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a>) is up&nbsp;<font color='green'>20%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16942865-u-s-fda-grants-fast-track-designation-pluristems-plx-pad-treatment-critical-limb-ischemia-cli\" target=\"_blank\">announcement </a>that the FDA has designated Phase 3-stage PLX-PAD cell therapy for Fast Track review for the treatment of critical limb ischemia &#40;CLI&#41; in patients who are not candidates for revascularization.</li><li>Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the marketing application.</li><li>PLX cells are mesenchymal-like adherent stromal cells derived from full-term human placentas that may be administered without the need for HLA matching. According to the company,&nbsp;<a href=\"http://www.pluristem.com/mechanism-of-action/\" target=\"_blank\">PLX-PAD</a>&nbsp;(peripheral artery disease) cells have demonstrated the ability to stimulate the growth of new blood vessels in preclinical models inducing muscle tissue regeneration and improving muscle function.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296012\" data-linked=\"Pluristem&#39;s PLX-PAD Fast Track&#39;d for critical limb ischemia; shares ahead 20% premarket\" data-tweet=\"$PSTI - Pluristem&#39;s PLX-PAD Fast Track&#39;d for critical limb ischemia; shares ahead 20% premarket https://seekingalpha.com/news/3296012-pluristems-plx-pad-fast-trackd-for-critical-limb-ischemia-shares-ahead-20-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3296012-pluristems-plx-pad-fast-trackd-for-critical-limb-ischemia-shares-ahead-20-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296011\" data-ts=\"1505740334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296011-bofaml-ups-nvidia-price-target-to-near-street-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML ups Nvidia price target to near Street high</a></h4><ul><li>        Bank of America Merrill Lynch <a href=\"https://www.cnbc.com/2017/09/18/nvidia-at-all-time-high-as-merrill-lynch-gushes-over-a-i.html\" target=\"_blank\">raises</a> its Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) price target from $185 to $210 and reiterates a Buy rating.</li><li>               Analyst Vivek Arya calls Nvidia a &ldquo;top pick&rdquo; and says the firm&rsquo;s positive view on the company &ldquo;is based on its underappreciated transformation from a traditional PC graphics vendor, into a supplier into high end gaming, enterprise graphics, cloud, accelerated computing and automotive markets.&rdquo;&nbsp;</li><li>                  The analyst sees AI as a major potential tailwind for Nvidia.    </li><li>               Arya forecasts data center capital spending to rise 21% next year, up from 16.5% this year.&nbsp;</li><li>               BofAML now has the second highest price target on Nvidia behind only Evercore ISI with a $250 target.</li><li>Nvidia shares are&nbsp;<font color='green'>up 2.77%</font>&nbsp;premarket. &nbsp; &nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3296011\" data-linked=\"BofAML ups Nvidia price target to near Street high\" data-tweet=\"$NVDA - BofAML ups Nvidia price target to near Street high https://seekingalpha.com/news/3296011-bofaml-ups-nvidia-price-target-to-near-street-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3296011-bofaml-ups-nvidia-price-target-to-near-street-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296008\" data-ts=\"1505740105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296008-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-13%</font>.</li><li><a href='https://seekingalpha.com/symbol/NEOS' title='Neos Therapeutics'>NEOS</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/STNG' title='Scorpio Tankers Inc.'>STNG</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3295929-scorpio-tankers-misses-0_01-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3296008\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$HMNY $NEOS $STNG - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3296008-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3296008-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296007\" data-ts=\"1505739970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTIE\" target=\"_blank\">PTIE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296007-pain-therapeutics-nabs-2_2m-nida-grant-shares-ahead-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pain Therapeutics nabs $2.2M NIDA grant; shares ahead 12% premarket</a></h4><ul><li>Thinly traded nano cap Pain Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a>) is up&nbsp;<font color='green'>12%</font>&nbsp;premarket on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16942857-national-institute-drug-abuse-awards-pain-therapeutics-2_2-million-grant\" target=\"_blank\">announcement </a>that it has been awarded a $2.2M grant from the National Institute on Drug Abuse &#40;NIDA&#41; to support development of pain candidate FENROCK, an abuse-deterrent transdermal patch&nbsp;formulation of fentanyl.</li><li>The company says drug abusers can access fentanyl on other patches by chewing them or extracting the opioid for injection which can lead to addiction, overdose and death.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296007\" data-linked=\"Pain Therapeutics nabs $2.2M NIDA grant; shares ahead 12% premarket\" data-tweet=\"$PTIE $SAVA - Pain Therapeutics nabs $2.2M NIDA grant; shares ahead 12% premarket https://seekingalpha.com/news/3296007-pain-therapeutics-nabs-2_2m-nida-grant-shares-ahead-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3296007-pain-therapeutics-nabs-2_2m-nida-grant-shares-ahead-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296000\" data-ts=\"1505739301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMPI\" target=\"_blank\">DMPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296000-fda-allows-delmar-pharmas-additional-ind-application-of-valminus-083-for-treatment-of-ovarian\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA allows DelMar Pharma&#39;s additional IND application of VAL-083 for the treatment of ovarian cancer; shares ahead 8% premarket</a></h4><ul> <li>DelMar Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a>) <a href=\"https://seekingalpha.com/pr/16943052-delmar-pharmaceuticals-receives-ind-allowance-fda-initiate-clinical-trials-valminus-083\" target=\"_blank\">announces</a> that the FDA has allowed an additional Investigational New Drug Application to study its lead drug candidate <a href=\"http://www.delmarclinicaltrials.com/val-083\" target=\"_blank\">VAL-083</a> as a potential treatment for ovarian cancer.</li>   <li>DelMar's clinical trial will be a multi-center, Phase 1/2 Study of VAL-083 in patients with Recurrent Platinum Resistant Ovarian Cancer. VAL-083 has the potential to overcome chemo-resistance to platinum-based chemotherapy in ovarian, lung and other solid tumors.</li>    <li>VAL-083 activity against platinum-resistant ovarian cancer will be measured based on ORR using the&nbsp;Response Evaluation Criteria in Solid Tumors as well as response duration, progression free survival, and a measurement of CA-125 biomarker levels in the blood. The study's primary endpoint is to demonstrate an ORR benefit compared to historical control of 12-15%.</li>    <li>VAL-083 (dianhydrogalactitol),&nbsp;an orphan drug designation&nbsp;is a DNA-targeting agent that introduces interstrand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death.</li><li>Shares are up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296000\" data-linked=\"FDA allows DelMar Pharma&#39;s additional IND application of VAL-083 for the treatment of ovarian cancer; shares ahead 8% premarket\" data-tweet=\"$DMPI - FDA allows DelMar Pharma&#39;s additional IND application of VAL-083 for the treatment of ovarian cancer; shares ahead 8% premarket https://seekingalpha.com/news/3296000-fda-allows-delmar-pharmas-additional-ind-application-of-valminus-083-for-treatment-of-ovarian?source=tweet\" data-url=\"https://seekingalpha.com/news/3296000-fda-allows-delmar-pharmas-additional-ind-application-of-valminus-083-for-treatment-of-ovarian\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296003\" data-ts=\"1505739300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITRI\" target=\"_blank\">ITRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296003-silver-spring-networks-bought-itron-shares-up-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Silver Spring Networks bought by Itron; shares up 25%</a></h4><ul><li>Itron (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRI' title='Itron, Inc.'>ITRI</a>) <a href=\"http://www.reuters.com/article/us-silverspring-m-a-itron/itron-to-buy-silver-spring-to-boost-smart-grid-presence-idUSKCN1BT18F\" target=\"_blank\">will buy</a> Silver Spring Networks (NYSE:<a href='https://seekingalpha.com/symbol/SSNI' title='Silver Spring Networks'>SSNI</a>) in a deal valued at $830M excluding $118M in cash.</li><li>Itron makes energy and water usage monitoring tech and Silver Spring Networks produces equipment and services to change power grids into smart grids.</li><li>Silver Spring shareholders will receive $16.25 per share.</li><li>Itron will finance the deal through cash and about $750M in new debt.</li><li>Silver Spring shares are&nbsp;<font color='green'>up 24.62%&nbsp;</font>premarket.</li><li>Correction: updated to correct typos in company name.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296003\" data-linked=\"Silver Spring Networks bought by Itron; shares up 25%\" data-tweet=\"$ITRI $ITRI $SSNI - Silver Spring Networks bought by Itron; shares up 25% https://seekingalpha.com/news/3296003-silver-spring-networks-bought-itron-shares-up-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3296003-silver-spring-networks-bought-itron-shares-up-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295991\" data-ts=\"1505738079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295991-rbc-capital-upgrades-applied-materials\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC Capital upgrades Applied Materials</a></h4><ul><li>        RBC Capital <a href=\"https://www.streetinsider.com/Analyst+PT+Change/RBC+Capital+Upgrades+Applied+Materials+%28AMAT%29+to+Outperform%2C+Bullish+Ahead+Of+Analyst+Day/13302589.html\" target=\"_blank\">upgrades</a> Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>) from Sector Perform to Outperform with the price target upped from $48 to $55.</li><li>                  Analyst Amit Daryanani remains bullish ahead of the September 27 analyst day.    </li><li>               The analyst expects Applied Materials to report EPS of $4 to $5 by 2020 due to growth stability, display and share repurchase tailwinds, and margin expansion.</li><li>                  Applied Materials shares are&nbsp;<font color='green'>up 1.44%&nbsp;</font>premarket.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3295991\" data-linked=\"RBC Capital upgrades Applied Materials\" data-tweet=\"$AMAT - RBC Capital upgrades Applied Materials https://seekingalpha.com/news/3295991-rbc-capital-upgrades-applied-materials?source=tweet\" data-url=\"https://seekingalpha.com/news/3295991-rbc-capital-upgrades-applied-materials\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295986\" data-ts=\"1505737976\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295986-teva-sells-remaining-assets-in-womens-health-unit-for-1_38b-shares-ease-1-premarket-rbc-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva sells remaining assets in women&#39;s health unit for $1.38B; shares ease 1% premarket as RBC says turnaround to be &quot;prolonged&quot;</a></h4><ul><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) inks <a href=\"https://seekingalpha.com/pr/16943073-teva-announces-sale-remaining-assets-specialty-global-women-s-health-portfolio-1_38-billion\" target=\"_blank\">two agreements</a> to sell the remaining assets in its specialty global women's health business for $1.38B. Proceeds, including the recently announced sale of PARAGARD, will be used to pay down debt.</li><li>The first deal involves the sale of a portfolio of products, including Ovaleap, Zoely, Seasonique and Colpotrophine, to CVC Capital Partners Fund VI for $703M in cash. The group accounted for $258M in sales in 2016.</li><li>The second deal is with Foundation Consumer Healthcare to sell Plan B One-Step and Teva's emergency contraceptive brands for $675M in cash. The products generated $140M in sales in 2016.</li><li>The transactions should close by year-end.</li><li>RBC's Randall Stanicky has cut the price target on the stock to $15 (UNDERPERFORM) citing the company's \"prolonged turnaround.\" He doesn't seed its leverage ratio falling to 3x EBITDA until 2020 (it's 5.5x now).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294738-teva-sells-paragard-asset-coopersurgical-1_1b\" target=\"_blank\">Teva sells Paragard asset to CooperSurgical for $1.1B</a> (Sept. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295986\" data-linked=\"Teva sells remaining assets in women&#39;s health unit for $1.38B; shares ease 1% premarket as RBC says turnaround to be &quot;prolonged&quot;\" data-tweet=\"$TEVA - Teva sells remaining assets in women&#39;s health unit for $1.38B; shares ease 1% premarket as RBC says turnaround to be &quot;prolonged&quot; https://seekingalpha.com/news/3295986-teva-sells-remaining-assets-in-womens-health-unit-for-1_38b-shares-ease-1-premarket-rbc-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3295986-teva-sells-remaining-assets-in-womens-health-unit-for-1_38b-shares-ease-1-premarket-rbc-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295988\" data-ts=\"1505737630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASML\" target=\"_blank\">ASML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295988-susquehanna-upgrades-asml\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna upgrades ASML</a></h4><ul><li>        Susquehanna <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Susquehanna+Upgrades+ASML+Inc.+%28ASML%29+to+Positive/13303046.html\" target=\"_blank\">upgrades</a> ASML (NASDAQ:<a href='https://seekingalpha.com/symbol/ASML' title='ASML Holding N.V.'>ASML</a>) from Neutral to Positive and ups the price target by $60 to $190.</li><li>               Analyst Mehdi Hosseini calls ASML &ldquo;the best positioned SCE company looking forward&rdquo; and cites Moore&rsquo;s Law as the sustainable force behind the company&rsquo;s current MPU and DRAM businesses.&nbsp;</li><li>               ASML shares are&nbsp;<font color='green'>up 1.24%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3295988\" data-linked=\"Susquehanna upgrades ASML\" data-tweet=\"$ASML - Susquehanna upgrades ASML https://seekingalpha.com/news/3295988-susquehanna-upgrades-asml?source=tweet\" data-url=\"https://seekingalpha.com/news/3295988-susquehanna-upgrades-asml\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295982\" data-ts=\"1505736848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATNX\" target=\"_blank\">ATNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295982-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Athenex (NASDAQ:<a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a>) initiated with Outperform rating and $25 price target by Credit Suisse.</li><li>GenMark Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/GNMK' title='GenMark Diagnostics, Inc.'>GNMK</a>) initiated with Buy rating and $13 price target by BofAMerrill Lynch.</li><li>Mednax (NYSE:<a href='https://seekingalpha.com/symbol/MD' title='Mednax, Inc.'>MD</a>) upgraded to Overweight with a $51 price target by Keybanc.</li><li>Arrowhead Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a>) upgraded to Outperform by William Blair. Shares up&nbsp;<font color='green'>8%</font>&nbsp;premarket.</li><li>Tactile Systems Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/TCMD' title='Tactile Systems Technology'>TCMD</a>) downgraded to Neutral by BTIG.</li><li>Teladoc (NYSE:<a href='https://seekingalpha.com/symbol/TDOC' title='Teladoc Health, Inc.'>TDOC</a>) downgraded to Neutral with a $36 price target by Baird.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) price target lowered to $15 from $21 by RBC Capital Markets citing a prolonged turnaround.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3295982\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$ATNX $ATNX $GNMK - Premarket analyst action - healthcare https://seekingalpha.com/news/3295982-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3295982-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295981\" data-ts=\"1505736727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRXC\" target=\"_blank\">TRXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295981-transenterix-reports-progress-on-senhance-fda-submission\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransEnterix reports progress on Senhance FDA submission</a></h4><ul> <li>TransEnterix (NYSEMKT:<a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a>) has <a href=\"https://seekingalpha.com/pr/16942801-transenterix-inc-reports-progress-senhance-fda-submission\" target=\"_blank\">filed</a> its response to the FDA's additional information request related       to the Company&rsquo;s Senhance Surgical Robotic System 510(k) submission.</li>          <li>Todd M. Pope, President and CEO says, &ldquo;The submission of our response is a       key step towards achieving 510(k) clearance for the Senhance, which we       continue to expect in 2017.&rdquo;</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3295981\" data-linked=\"TransEnterix reports progress on Senhance FDA submission\" data-tweet=\"$TRXC - TransEnterix reports progress on Senhance FDA submission https://seekingalpha.com/news/3295981-transenterix-reports-progress-on-senhance-fda-submission?source=tweet\" data-url=\"https://seekingalpha.com/news/3295981-transenterix-reports-progress-on-senhance-fda-submission\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295978\" data-ts=\"1505736423\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRUS\" target=\"_blank\">CRUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295978-bofaml-says-cirrus-logics-iphone-content-might-peak-in-fy18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML says Cirrus Logic&#39;s iPhone content might peak in FY18</a></h4><ul><li>        Bank of America Merrill Lynch initiates Cirrus Logic (NASDAQ:<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a>) at Underperform with a $50 price target.</li><li>               Analyst Adam Gonzalez writes that the company&rsquo;s iPhone content might peak in FY18 leading to slowed sales and earnings since Apple accounts for 75% to 80% of overall revenue.&nbsp;</li><li>               Gonzalez expects sales deceleration to reach 5% growth CAGR between FY17 and FY20 and 30% growth CAGR from FY15 to FY17.&nbsp;</li><li>               The analyst says Cirrus still has some opportunities including Android phones and digital headsets.&nbsp;</li><li>               Source: Bloomberg First Word&nbsp;</li><li>               Cirrus Logic shares are&nbsp;<font color='red'>down 1.64%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3295978\" data-linked=\"BofAML says Cirrus Logic&#39;s iPhone content might peak in FY18\" data-tweet=\"$CRUS - BofAML says Cirrus Logic&#39;s iPhone content might peak in FY18 https://seekingalpha.com/news/3295978-bofaml-says-cirrus-logics-iphone-content-might-peak-in-fy18?source=tweet\" data-url=\"https://seekingalpha.com/news/3295978-bofaml-says-cirrus-logics-iphone-content-might-peak-in-fy18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295968\" data-ts=\"1505736228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTX\" target=\"_blank\">BTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295968-biotime-awarded-grant-from-nih-shares-ahead-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioTime awarded grant from the NIH; shares ahead 4% premarket</a></h4><ul> <li>BioTime (NYSEMKT:<a href='https://seekingalpha.com/symbol/BTX' title='BioTime, Inc'>BTX</a>) <a href=\"https://seekingalpha.com/pr/16942842-biotime-awarded-grant-nih\" target=\"_blank\">announces</a> that it has been awarded a grant       of up to $1.56M from the Small Business Innovation Research       program of the National Institutes of Health.</li>     <li>The grant provides       funding to further develop restoration program for advanced retinal diseases and injuries.</li>          <li>3-dimensional retinal       tissue using pluripotent cell technology will be used in the restoration program to improve vision caused by       retinal degeneration and traumatic injury.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume.</li>          </ul><div class=\"tiny-share-widget\" data-id=\"3295968\" data-linked=\"BioTime awarded grant from the NIH; shares ahead 4% premarket\" data-tweet=\"$BTX $LCTX - BioTime awarded grant from the NIH; shares ahead 4% premarket https://seekingalpha.com/news/3295968-biotime-awarded-grant-from-nih-shares-ahead-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3295968-biotime-awarded-grant-from-nih-shares-ahead-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295973\" data-ts=\"1505736206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUN\" target=\"_blank\">HUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295973-huntsman-expects-strong-q3-results-despite-harvey-disruptions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huntsman expects strong Q3 results despite Harvey disruptions</a></h4><ul>     <li>Huntsman (NYSE:<a href='https://seekingalpha.com/symbol/HUN' title='Huntsman Corporation'>HUN</a>)&nbsp;<font color='green'>+2.2%</font> premarket after saying it <a href=\"https://seekingalpha.com/pr/16942823-huntsman-raises-third-quarter-2017-expectations-comments-impact-hurricane-harvey\" target=\"_blank\">expects strong Q3 results</a> - better than Q2 - despite the impact of Hurricane Harvey, which forced it to close six Texas chemical plants which are \"now operating or are in the process of returning to normal operations.\"</li>     <li>HUN estimates Harvey's impact to Q3 adjusted EBITDA at $35M-$40M, mostly in the Performance Products segment, which declared force majeure on ethylene oxide, ethylene glycol, ethanolamines and other ethylene oxide derivative products.</li><li>Q3 results will exclude the Pigments and Additives division, which will be reported in discontinued operations.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3295973\" data-linked=\"Huntsman expects strong Q3 results despite Harvey disruptions\" data-tweet=\"$HUN - Huntsman expects strong Q3 results despite Harvey disruptions https://seekingalpha.com/news/3295973-huntsman-expects-strong-q3-results-despite-harvey-disruptions?source=tweet\" data-url=\"https://seekingalpha.com/news/3295973-huntsman-expects-strong-q3-results-despite-harvey-disruptions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295970\" data-ts=\"1505736071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSII\" target=\"_blank\">CSII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295970-cardiovascular-systems-cuts-fiscal-q1-guidance-due-to-hurricane-impact\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardiovascular Systems cuts fiscal Q1 guidance due to hurricane impact</a></h4><ul><li>Citing the impact of Hurricanes Harvey and Irma on procedure volumes in Houston and Florida, Cardiovascular Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CSII' title='Cardiovascular Systems, Inc.'>CSII</a>)&nbsp;<a href=\"https://seekingalpha.com/pr/16942849-cardiovascular-systems-announces-anticipated-revenue-impact-hurricanes-harvey-irma\" target=\"_blank\">reduces </a>its fiscal Q1 guidance below its previously announced range of $52.6M - 53.6M. The company says it will provide the new range after it knows more about when normal operations will resume in the affected areas.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295970\" data-linked=\"Cardiovascular Systems cuts fiscal Q1 guidance due to hurricane impact\" data-tweet=\"$CSII - Cardiovascular Systems cuts fiscal Q1 guidance due to hurricane impact https://seekingalpha.com/news/3295970-cardiovascular-systems-cuts-fiscal-q1-guidance-due-to-hurricane-impact?source=tweet\" data-url=\"https://seekingalpha.com/news/3295970-cardiovascular-systems-cuts-fiscal-q1-guidance-due-to-hurricane-impact\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295964\" data-ts=\"1505735178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBRV\" target=\"_blank\">NBRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295964-nabrivas-lefamulin-successful-in-late-stage-cabp-study-shares-ahead-92-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nabriva&#39;s lefamulin successful in late-stage CABP study; shares ahead 92% premarket</a></h4><ul><li>Thinly traded micro cap Nabriva Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a>) is up&nbsp;<font color='green'>92%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16942866-nabriva-therapeutics-announces-positive-topline-results-global-phase-3-clinical-trial\" target=\"_blank\">announcement </a>of positive top-line results from a Phase 3 clinical trial, LEAP 1, evaluating intravenous to oral lefamulin in patients with community-acquired bacterial pneumonia &#40;CABP&#41;.</li><li>The study, the first two pivotal trials, met its primary endpoint of non-inferiority (no worse than) to moxifloxacin, with or without adjunctive linezolid, for early clinical response &#40;ECR&#41;&nbsp;assessed 72 - 120 hours following initiation of therapy in the intent-to-treat population. Specifically, the ECR rates were 87.3% for lefamulin and 90.2% for moxifloxacin with/without linezolid.</li><li>The safety profiles were similar between the two drugs.</li><li>Top-line from the second Phase 3, LEAP 2, should be available in late Q1/early Q2 2018.</li><li>Lefamulin is a new class of antibiotic called a&nbsp;<a href=\"https://en.wikipedia.org/wiki/Pleuromutilin\" target=\"_blank\">pleuromutilin</a>.</li><li>More detailed results will be submitted for presentation at future medical conferences.</li><li>The company will host a conference call this morning at 8:30 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295964\" data-linked=\"Nabriva&#39;s lefamulin successful in late-stage CABP study; shares ahead 92% premarket\" data-tweet=\"$NBRV - Nabriva&#39;s lefamulin successful in late-stage CABP study; shares ahead 92% premarket https://seekingalpha.com/news/3295964-nabrivas-lefamulin-successful-in-late-stage-cabp-study-shares-ahead-92-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3295964-nabrivas-lefamulin-successful-in-late-stage-cabp-study-shares-ahead-92-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295962\" data-ts=\"1505734711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPL\" target=\"_blank\">UPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295962-fir-tree-to-pursue-strategic-alternatives-for-ultra-petroleum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fir Tree to pursue strategic alternatives for Ultra Petroleum</a></h4><ul>     <li>Ultra Petroleum (NASDAQ:<a href='https://seekingalpha.com/symbol/UPL' title='Ultra Petroleum Corp.'>UPL</a>) <font color='green'>+2.2%</font> premarket after Fir Tree Partners, its largest shareholder, says it plans to engage with the company to \"<a href=\"http://www.prnewswire.com/news-releases/fir-tree-partners-announces-intention-to-pursue-value-maximizing-strategic-alternatives-for-ultra-petroleum-corp-300520931.html\" target=\"_blank\">pursue value-maximizing strategic alternatives</a>.\"</li>     <li>\"UPL is the most attractive natural gas company in the U.S. and trades at a substantial and unwarranted discount to its pure play comps,\" Fir Tree says. \"Its deep, low-cost inventory, significant resource growth potential and absence of throughput issues that plague its Northeast peers is fully unrecognized in its current share price.\"</li>     <li>Fir Tree has direct control over 18.53% of UPL common shares and total economic interest in 22.12% of the shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295962\" data-linked=\"Fir Tree to pursue strategic alternatives for Ultra Petroleum\" data-tweet=\"$UPL $UPLC - Fir Tree to pursue strategic alternatives for Ultra Petroleum https://seekingalpha.com/news/3295962-fir-tree-to-pursue-strategic-alternatives-for-ultra-petroleum?source=tweet\" data-url=\"https://seekingalpha.com/news/3295962-fir-tree-to-pursue-strategic-alternatives-for-ultra-petroleum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}